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Summary 
 
Introduction 
Several parallels may be drawn between pregnancy and cancer. In the course of embryo 
implantation, trophoblast cells are able to proliferate and invade into maternal tissues, while a 
complex interaction with the maternal immune system ensures immune tolerance. Similarly, 
many tumors are able to grow invasively and mask themselves from the immune system. 
Many of the underlying mechanisms governing embryo implantation and tumor progression 
seem to lie in close proximity. Among them, the JAK/STAT pathway has been implicated in 
the transduction of a multitude of signals governing cell differentiation, proliferation, 
migration and apoptosis. Leukemia Inhibitory Factor (LIF) is a cytokine maximally expressed 
at the time of implantation that signals through the JAK/STAT pathway. Although its roles 
have not been completely understood, LIF is assumed to facilitate embryo implantation and 
regulate tumor invasion through the activity of STAT3. In this sense, this work intended to 
better clarify the role of LIF and the JAK/STAT pathway in choriocarcinoma cell lines, which 
are considered models for studying trophoblast physiology.  
 
Methods 
Different choriocarcinoma cell lines have been stimulated with LIF and IL-6 in order to 
investigate if these cytokines were associated with the tyrosine phosphorylation of STAT3, 
detected by Western blot. Considering that these cytokines are known to signal through the 
JAK/STAT pathway, Western blot has been performed to assess the constitutive expression 
and phosphorylation of three Janus kinases (JAKs) that might be involved in the LIF signaling 
pathway. Immunocytochemistry has been performed to validate some of these results. 
Additionally, this technique has been performed to assess the constitutive expression of the 
three Janus kinases in placental tissues of a healthy woman undergoing elective abortion. 
Once determined which Janus kinase had been expressed and phosphorylated upon LIF 
stimulation in the choriocarcinoma cell lines, a set of experiments aiming to silence kinase 
expression specifically has been performed. Trying to achieve this goal, different transfection 
reagents and siRNA concentrations have been tested for RNA interference targeting JAK1. 
Knock-down efficiency has been evaluated by Western blot. Finally, a set of functional tests 
has been performed to evaluate if LIF treatment and/or kinase silencing might modify cell 
behavior. In this sense, flow cytometry has been used to quantify cell proliferation, migration 
and invasion rates. 
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Results 
As demonstrated by Western blot, LIF stimulation correlated with the phosphorylation of 
STAT3 in the choriocarcinoma cell lines, as opposite to IL-6. The constitutive expression and 
phosphorylation of JAKs were differently distributed among cells. JAR cells expressed JAK1 
and JAK2 constitutively, and LIF stimulation induced phosphorylation of JAK1 in these cells. 
JEG-3 cells expressed JAK2 just to a marginal degree, and its phosphorylated form did not 
alter after LIF stimulation. Constitutive or activated JAK3 were not identified in both cell 
groups. Immunocytochemistry demonstrated similar results concerning the JAK isoforms 
constitutively expressed in these cells. Similarly, JAK1 and JAK2, but not JAK3, were 
identified in placental tissues, mainly in the villous trophoblast. 
As JAK1 was demonstrated to be constitutively expressed and phosphorylated after LIF 
stimulation in JAR cells, this isoform was chosen as target in the experiments of RNA 
interference. Maximal silencing rates (about 65% JAK1 knock-down) were achieved using 
Oligofectamine for transfection of the siRNA. In the functional experiments, LIF stimulation 
correlated with a significant increase in the proliferation rate of JAR cells. JAK1 knock-down 
induced a decrease in migratory cell behavior.  
 
Discussion  
The results of this work bring some help to understand the possible actors playing a role in 
cytokine signaling within the JAK/STAT pathway in choriocarcinoma cells. This pathway 
represents the principal signaling mechanism for a wide group of growth factors and 
cytokines in animals. The constitutive expression of three JAKs has been revealed in different 
choriocarcinoma cell lines and placentary tissues, evidencing similar profiles. Furthermore, it 
has been investigated how these JAK isoforms are influenced by LIF, a cytokine considered 
indispensable during placentation in several species and that is involved in regulation of 
tumor progression. LIF has also been demonstrated to induce STAT3 activation in all 
choriocarcinoma cell lines investigated in this work. STAT3 is implicated in neoplastic cell 
behavior, playing a role in cell motility and invasive growth. In this sense, it was 
demonstrated that LIF influences the behavior of JAR cells, increasing its proliferation rate. 
Reduction of JAK1 expression, achieved by RNA interference, correlated with altered cell 
behavior, posing the JAK/STAT pathway as a possible target of molecular based therapies. 
The clarification of the multitude of factors and signaling pathways regulating cell 
proliferation and invasion, both in the physiological and pathological settings, may lead to the 
development of new therapies targeting cancer and pregnancy related pathologies. 
Zusammenfassung 
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Zusammenfassung 
 
Einleitung 
Zwischen einer Schwangerschaft und der Entstehung von Krebserkrankungen lassen sich 
verschiedene Parallelen ziehen. Im Rahmen der Implantationsphase des Embryos proliferieren 
und invadieren Trophoblastzellen ins mütterliche Gewebe, während eine komplexe Interaktion 
mit dem mütterlichen Immunsystem eine Immuntoleranz gewährleistet. In ähnlicher Weise sind 
viele Tumoren in der Lage, invasiv zu wachsen und sich vor dem Immunsystem zu maskieren. So 
scheinen sich die grundlegenden Mechanismen, die Embryoimplantation und Tumorprogression 
regulieren, zu ähneln. Der Janus Kinase / Signal Transducer and Activator of Transduction 
(JAK/STAT)-Signalweg spielt eine Rolle in der Transduktion einer Vielzahl von Signalen, die 
Zelldifferenzierung, Proliferation, Migration und Apoptose regulieren. Leukemia Inhibitory 
Factor (LIF) ist ein Zytokin mit maximaler Expressionsrate während der Implantationsphase und 
signalisiert über den JAK/STAT-Signalweg. Obwohl die Funktion von LIF noch nicht endgültig 
geklärt ist, wird vermutet, dass es durch die Aktivierung von STAT3 die Embryoimplantation 
unterstützt und Tumorinvasion verstärkt. Die Intention dieser Arbeit war, die Rolle von LIF sowie 
die des JAK/STAT-Signalweges in Chorionkarzinom-Zelllinien näher zu analysieren, die häufig 
als Modelle für Studien der Physiologie von Trophoblasten genutzt werden. 
 
Methoden 
Verschiedene Chorionkarzinom-Zelllinien wurden mit LIF und IL-6 stimuliert, um die Wirkung 
dieser Zytokine auf die Tyrosinphosphorylierung von STAT3 zu untersuchen. Nachgewiesen 
wurde dies mittels Western blot. Da die Übertragung des LIF-Signals vom Rezeptor auf die 
STAT-Moleküle über die Phosphorylierung von drei verschiedenen Januskinasen vermittelt 
werden kann, wurden diese ebenfalls mittels Western blot untersucht. Anschließend wurde 
Immunzytochemie durchgeführt, um die Ergebnisse zu bestätigen. Weiterhin wurde diese 
Methode angewendet, um die  natürliche Expression der drei Januskinasen im Plazentagewebe 
einer gesunden Frau mit elektivem Abort zu untersuchen. Nachdem ermittelt wurde, welche 
Januskinasen nach LIF-Stimulation in den Chorionkarzinom-Zelllinien exprimiert und 
phosphoryliert werden, folgten Experimente zum Etablieren eines spezifischen Knockdowns der 
Kinaseexpression. Hierfür wurden verschiedene Transfektionsreagenzien und siRNA-
Konzentrationen für die RNA-Interferenz von JAK1 getestet. Die Effizienz des Knockdowns 
wurde mittels Western blot evaluiert. Im Anschluss an diese Experimente folgten funktionelle 
Tests, um zu untersuchen, ob eine Behandlung mit LIF und/oder ein Knockdown der Kinase, 
Einfluss auf das Zellverhalten haben. Mithilfe der Durchflusszytometrie wurden Proliferations-, 
Migrations- und Invasionsraten der Zellen quantifiziert. 
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Ergebnisse 
Wie im Western blot demonstriert wurde, korrelierte die Stimulation mit LIF mit der 
Phosphorylierung von STAT3 in Chorionkarzinom-Zelllinien. Die Stimulation mit IL-6 hingegen 
blieb ohne Effekt. Die Zellen zeigten hinsichtlich der natürlichen Expression und 
Phosphorylierung von Januskinasen Unterschiede. Eine natürliche Expression von JAK1 und 
JAK2 wurde in JAR-Zellen nachgewiesen, und die Stimulation mit LIF induzierte eine 
Phosphorylierung von JAK1. In JEG-3 Zellen sahen wir nur eine geringe Expression von JAK2, 
und die phosphorylierte Form zeigte nach LIF-Stimulation keinerlei Veränderung. Natürliches 
oder aktiviertes JAK3 konnten in keiner der beiden Zelllinien nachgewiesen werden. Die 
Immunzytochemie zeigte ähnliche Ergebnisse hinsichtlich der natürlichen Expression der JAK- 
Isoformen in diesen Zellen. JAK1 sowie JAK2, nicht aber JAK3, wurden in Plazentagewebe, 
hauptsächlich in villösen Trophoblasten, nachgewiesen. JAK1 wurde für die RNA-Interferenz 
gewählt, da es eine natürliche Expression in den JAR-Zellen zeigte, sowie nach LIF-Stimulation 
in phosphorylierter Form vorlag. Maximale Knockdown-Raten (ca. 65% JAK1 Knockdown) 
wurden mit Oligofectamin als Transfektionsreagens erzielt. In funktionellen Tests korrelierte die 
LIF-Stimulation mit einem signifikanten Anstieg der Proliferationsrate der JAR-Zellen. Der 
Knockdown von JAK1 induzierte eine Abnahme im Migrationsverhalten der Zellen. 
 
Diskussion 
Die Ergebnisse dieser Arbeit sollen für ein besseres Verständnis der Faktoren beitragen, die eine 
Rolle bei der Zytokinregulierung im JAK/STAT-Signalweg in Chorionkarzinomzellen spielen. 
Dieser Signalweg repräsentiert den Hauptsignalmechanismus für eine breite Gruppe von 
Wachstumsfaktoren und Zytokinen in Tieren. Die natürliche Expression der drei Januskinasen 
wurde in ähnlicher Form in verschiedenen Chorionkarzinom-Zelllinien als auch in 
Plazentagewebe gefunden. Weiterhin wurde untersucht, wie diese Isoformen durch LIF 
beeinflusst werden. Das Zytokin LIF wird als unentbehrlich während der Plazentationsphase in 
verschiedenen Spezies betrachtet und ist in die Regulierung von Tumorprogression involviert. Es 
wurde gezeigt, dass LIF eine STAT3-Aktivierung in allen untersuchten Chorionkarzinom-
Zelllinien induziert. STAT3 spielt eine Rolle bei Zellbeweglichkeit, invasivem Wachstum und 
steht auch in Zusammenhang mit neoplastischem Zellverhalten. Dahingehend konnte demonstriert 
werden, dass LIF die Proliferationsrate von JAR-Zellen erhöht. Eine reduzierte JAK1-Expression 
durch RNA-Interferenz korrelierte mit verändertem Zellverhalten. Somit könnte der JAK/STAT-
Signalweg als ein mögliches Ziel für molekül-basierte Therapien fungieren. Die Erforschung der 
Vielzahl von Faktoren und Signalwege, die Zellproliferation und –invasion regulieren, könnte zur 
Entwicklung neuer Therapien sowohl bei Krebserkrankungen als auch bei Schwangerschafts-
assoziierten Erkrankungen beitragen. 
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1. Introduction 
 
Pregnancy is a natural event that constitutes an enormous challenge to the maternal organism. 
The maternal immune system faces, during pregnancy, a situation in which it must tolerate 
and support the growth and development of the semi-allogeneic invading embryo. At the 
same time it combats potential pathogens that might impair gestational progression. In the 
course of embryo implantation, trophoblast cells are able to proliferate, migrate and invade 
into maternal tissues, while a complex interaction with the maternal immune system ensures 
the necessary immune tolerance. Interestingly, several parallels may be drawn between 
pregnancy and malignancies. Many tumors, resembling trophoblast cells, are able to grow 
invasively and to mask themselves from the immune system. The underlying mechanisms 
governing embryo implantation and tumor progression seem to lie in close proximity. The 
clarification of the multitude of factors and signaling pathways regulating cell invasion, both 
in the physiological and pathological settings, may lead to the development of new therapies 
targeting pregnancy related pathologies and cancer.  
 
 
1.1 – Blastocyst Implantation and Trophoblast Invasion 
 
Implantation of the human blastocyst into the maternal endometrium occurs at the 6th or 7th 
day after conception. For successful implantation, the blastocyst must firstly adhere to the 
luminal epithelium of a receptive endometrium (Herrler et al. 2003). The period of 
endometrial receptivity is known as “window of implantation” and is limited to the mid-
secretory phase of the menstrual cycle (about days 19-23 of a standard 28-day cycle) 
(Psychoyos 1973). Important modifications of the endometrium elicited by estrogen and 
progesterone have occurred up to this phase and constitute a prerequisite to a successful 
implantation. The set of endometrial modifications culminates in the formation of the decidua 
(in a process generally referred to as decidualization). Among others, these modifications 
include (Dimitriadis et al. 2010): 
- altered expression of extracellular matrix and cell surface molecules in the endometrial 
luminal epithelium, 
- increased secretion by endometrial glands,  
- differentiation of the periarteriolar fibroblasts in the stroma, 
- influx of maternal immune cells (mainly natural killer cells) into the uterus. 
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Upon attachment to the receptive endometrium, blastocyst cells proliferate and start to 
migrate across the endometrial luminal epithelium, infiltrating into the maternal tissues. The 
so-called trophoblast derivates from the external layer of the blastocyst (called trophectoderm) 
and constitutes the extra-embryonic tissue that is directly involved in the processes of 
proliferation, migration and invasion, finally forming the placenta. The trophoblast comprises 
different populations of cells, such as the actively proliferating cytotrophoblast, also referred 
to as trophoblast stem cells, from which further differentiation will originate different cell 
subsets (Ferretti et al. 2007).  
The process of blastocyst adhesion to the endometrial epithelium is believed to trigger the 
differentiation of the cytotrophoblast into two distinct subsets, the villous and extravillous 
populations (Fig. 01) (Armant 2005). In the villous pathway, the villous cytotrophoblast 
remains in the fetal compartment and fuses to form the syncytiotrophoblast, a multinucleated 
structure with endocrinal activity into which the blastocyst embeds (Bischof and Campana 
1997). Since it covers the floating chorionic villi and the intervillous space, the 
syncytiotrophoblast is in direct contact with the maternal blood and thus participates in the 
fetal-maternal exchange. In the extravillous pathway, the extravillous cytotrophoblast (EVT) 
forms the stratified cylinder-shaped structure called cell column, whose distal part 
differentiates into an invasive phenotype (Kaufmann and Castellucci 1997). A subpopulation 
of the EVT, called interstitial EVT, infiltrates into the uterine decidua and anchors chorionic 
villi into the Nitabuch layer (the fibrinoid layer between the compact endometrium and the 
cytotrophoblastic shell). Another subpopulation, known as endovascular EVT, invades into a 
third of the depth of the spiral arteries in the myometrium and engrafts the maternal blood 
vessels, creating low resistance vessels that will provide adequate perfusion (assuring oxygen 
and nutrients) to the forming fetus (Genbacev et al. 1992, Dimitriadis et al. 2010). 
Meanwhile, during the process of embryo implantation, the decidua (including the 
decidualized stromal cells and maternal leukocytes) continues to develop and forms the 
uterine line that will constitute the maternal part of the placenta, where maternal cells are 
directly in contact with fetal cells (Veenstra van Nieuwenhoven et al. 2003). The decidua has 
been implicated in the regulation of trophoblast invasion and plays thus an essential role in 
pregnancy (Dimitriadis et al. 2010). The observation that uncontrolled trophoblast invasion 
occurs in sites where the decidua is partially or totally absent (as observed in ectopic 
pregnancies) supports this regulatory property of the decidua (Lockwood et al. 2008). 
Moreover, a correlation between human infertility and ineffective decidualization of 
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endometrial stromal cells has been identified in vitro (Karpovich et al. 2005), suggesting that 
the successful establishment of pregnancy depends on adequate decidualization. 
Finally, the process of trophoblast invasion, which had started in the early stages of embryo 
implantation, forms a continuum which extends during the whole pregnancy. Up to the 8th 
week of pregnancy, the uterine mucosa has been extensively colonized by interstitial EVT, 
which become rounded and multinucleated (forming the placental giant cells) (Ferretti et al. 
2007). These cells continue to invade the inner myometrium during the second and third 
trimester, although in a much more decreased intensity. In these phases, most of the 
interstitial EVT cells are morphologically giant cells. 
 
 
 
Fig. 01 Implanting blastocyst (Figure from Staun-Ram and Shalev 2005) 
Blastocyst implantation constitutes a complex process involving a multitude of factors 
regulating cell proliferation, migration and invasion. These factors are believed to be 
controlled by the blastocyst itself and the maternal microenvironment. The figure above 
highlights the interaction between the trophoblast and maternal endometrium, including 
cytokines, growth factors, integrins, proteases and hormones (Staun-Ram and Shalev 2005).  
 
Introduction 
 
8 
1.2 – The Immune System During Pregnancy  
 
For many years the fetal-maternal boundary had been believed to be an immunologically inert 
site, in which any contact between fetal antigens and maternal immune system should be 
avoided. The discovery of anti-paternal, anti-fetal and anti-placentary antibodies in the serum 
of pregnant women (Billington 1992) changed this premise, suggesting that the maternal 
immune system recognizes and reacts to fetal-derived antigens in a very controlled manner, in 
which embryo development is not disturbed. It is now accepted that recognition of fetal 
antigens by the maternal immune system is a prerequisite to a successful pregnancy outcome. 
This recognition leads to appropriate immunological tolerance, enabling the embryo to growth 
and develop, while harmful pathogens are combated (Szekeres-Bartho 2002, Schmitt et al. 
2008).  
Considering that about half of the antigens expressed by the fetus derives from the father 
(therefore potential targets of immune attack), it is not difficult to imagine that pregnancy 
represents a big challenge to the maternal immune system, which needs to recognize the 
embryo, a “semi-allograft organism”, without being harmful to it, at the same time that it 
needs to confront undesired pathogens. In these terms, several mechanisms have been shown 
to participate in the puzzle of immune tolerance, such as the expression of Major 
Histocompatibility Complex (MHC) molecules by the trophoblast and important changes in 
the balance between T-helper 1 (Th1) and T-helper 2 (Th2) cytokines. 
The trophoblast lack many of the classical MHC molecules (such as MHC classes Ia and II), 
but expresses a special non-polymorphic non-classical MHC Ib molecule – the Human 
Leukocyte Antigen G (HLA-G), which can be recognized by different decidual leukocyte 
populations (Exley and Boyson 2011). The non-expression of classical MHC molecules leads 
the trophoblast to express just a few paternal antigens – a mechanism used to escape from T-
cell-mediated lyses (Geis and Dietl 2001). Furthermore, HLA-G has been implicated in 
inhibition of the cytolytic activity of NK-cells, rescuing the embryo from a potentially 
harmful immune attack (King et al. 2000). HLA-G is mainly expressed by extravillous 
trophoblast cells, which keep direct contact with maternal immune cells in the decidua.  
The process of antigen identification is mediated by maternal γδT-cells, which are able to 
recognize molecules in a MHC-unrestricted manner and without antigen processing or 
presentation (Mincheva-Nilsson 2003). In the decidua of early pregnancy, more than half of 
the γδT-cells express PR, which is considered a marker for their activity. Active γδT-cells 
have been demonstrated to modulate maternal immune system towards immune tolerance. 
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They also act against undesired pathogens and regulate trophoblast invasion (Poehlmann et al. 
2006). 
 
Cytokines and Th1/Th2 Balance in Pregnancy  
 
Cytokines encompass a large family of signaling molecules, including proteins, peptides and 
glycoproteins. They play an essential role in several processes of intercellular communication, 
such as immune modulation (Gilman et al. 2001). For a successful implantation and fetal-
placental development, it is necessary to highlight the role of Th1 and Th2 cytokines during 
pregnancy.  
From the beginning of implantation up to term, important modifications are observed in the 
balance between these cytokines, and these changes are considered indispensable for a 
successful pregnancy outcome (Dealtry et al. 2000). Th1 cytokines, such as TNF, IL-2, IL-12 
and IFN-γ, induce inflammatory reaction and cytotoxicity upon activation of macrophages. 
They seem to be particularly important in the peri-implantation period, when they induce a 
local proinflammatory environment that has been suggested to facilitate initial trophoblast 
invasion (Joachim et al. 2003). Subsequently, an important shift towards Th2 dominance is 
observed as placentation begins, and this dominance is maintained up to the end of pregnancy 
(Dealtry et al. 2000). Th2 cytokines, such as IL-4, IL-6, IL-10, IL-13 and TFG-β, induce 
humoral immunity mediated by mast cells and eosinophils, and create an anti-inflammatory 
environment in the fetal-maternal interface that has been considered indispensable for 
successful placentation and fetal survival (Veenstra van Nieuwenhoven et al. 2003). 
In fact, disturbances in the balance of Th1/Th2 cytokines and the undesired dominance of Th1 
cytokines throughout pregnancy have been associated with impairment of trophoblast 
function and embryo development, culminating in recurrent abortion (Geis and Dietl 2001, 
Joachim et al. 2003). Furthermore, the physiological dominance of Th2 cytokines during 
pregnancy (and its consequent anti-inflammatory role) is recognizable by the fact that women 
suffering from autoimmune disorders (such as rheumatoid arthritis and collagenosis) usually 
encounter alleviation of their symptoms during pregnancy. On the other hand, the reduced 
cell-mediated immunity triggered by Th2 cytokines also determines an undesired increase in 
the incidence of viral infections and malignancies in pregnant women (Geis and Dietl 2001, 
Szekeres-Bartho et al. 2001). Finally, at the end of pregnancy, a new shift towards Th1 
dominance is achieved, and this restored pro-inflammatory environment is believed to play a 
role in the process of birth and in maternal and child immune defense (Dealtry et al. 2000).  
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1.3 – Parallels between Pregnancy and Cancer 
 
Blastocyst implantation and subsequent placentation depend on the capability of the newly 
formed extravillous trophoblast to invade into the uterine decidua and to engraft maternal 
blood vessels (Dimitriadis et al. 2010). This continuous process demands an appropriate and 
complex cross-talk between the mother and the forming fetus, in which several molecules 
participate, including growth factors, cytokines, chemokines, proteases and adhesion 
molecules (Salamonsen et al. 2009).  
Trophoblast invasion is a complex process that must be spatially and temporally regulated to 
ensure the proper development of a functional placenta and the establishment of pregnancy 
(Dimitriadis et al. 2010). Taken its proliferative and invasive properties, and considering the 
fact that the embryo possesses paternal antigens that might trigger maternal immunological 
reaction, the forming fetus can be ultimately considered a semi-allogeneic tissue, which is 
able to invade and induce host-immunotolerance (Murray and Lessey 1999). Interestingly, 
many malignancies mimic and abuse of these physiological mechanisms of cell invasion and 
immunological masking in disadvantage to the “host” (Fitzgerald et al. 2008). The highly 
proliferative phenotype of EVT cells closely resembles the tumorigenic phenotype of 
localized tumors after the neoplastic cell transformation (Gupta et al. 2005). In these terms, 
both trophoblast and tumor cells share an intense proliferative behavior and display a lack of 
cell-cell contact inhibition. Furthermore, the migratory and invasive phenotype of EVT cells 
is similar to the metastatic phenotype of tumor cells subsequent to their malignant 
transformation. Both cells subsets share here the aptitude to attach to the basement membrane 
and to promote it proteolysis, in an active process of membrane penetration (Poste and Fidler 
1980, Staff 2001). But differently from tumor cells, the physiological trophoblast invasion 
occurs in a tightly controlled manner (Bischof and Campana 2000, Kliman 1993). This is 
supported by the fact that trophoblast cells from term placenta possess a decreased ability to 
invade (Poehlmann et al. 2005).  
The similar mechanisms governing embryo implantation and tumor development, including 
their underlying cell signaling pathways, make the study of invasion an important task to be 
accomplished.  The knowledge about the extra and intra-cellular signals that regulate invasion 
remains meanwhile elusive, and the understanding of this complex process might thus 
contribute to elucidate tumor progression and guide the development of new approaches 
targeting cancer and pregnancy-related diseases.  
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Choriocarcinoma, a Gestational Trophoblastic Neoplasia 
 
Gestational trophoblastic disease (GTD) embraces a spectrum of benign and malignant 
tumors derived from the placental villous trophoblast (Lurain 2010). GTD is usually 
subdivided in: 
- hydatidiform mole (complete and partial), a benign but potentially deadly tumor; 
- gestational trophoblastic neoplasia (GTN), which encompasses invasive mole, 
choriocarcinoma and placental site trophoblastic tumor. 
GTN is composed of malignant tumors, which can invade and metastasize, leading invariably 
to death when untreated (Soper 2006, Berkowitz and Goldstein 2009). Among them, 
choriocarcinoma is a rare condition affecting about 1 in 40,000 pregnancies in Europe and 
North America (Brinton et al. 1986, Smith et al. 2003). It is characterized by the lack of 
chorionic villi, abnormal trophoblastic hyperplasia and anaplasia, necrosis and hemorrhage. 
Malignant cells are able to invade into myometrium and its blood vessels, commonly 
metastasizing to the lungs, liver, brain, pelvis and vagina. Choriocarcinoma arises in 50% of 
the cases from hydatidiform moles, but it can be associated with any pregnancy event, such as 
tubal pregnancy, preterm or term gestation (Lurain 1990). In fact, prior complete 
hydatidiform mole constitutes the principal risk factor for the development of 
choriocarcinoma, although less than 4% of moles progress to it (Lurain 1990). Advanced 
maternal age and ethnicity constitute further risk factors (the condition is more common in 
Asian descents and African Americans) (Palmer 1994, Smith et al. 2003). 
Clinically, postmolar choriocarcinoma usually presents as irregular bleeding subsequent to 
mole evacuation, in conjunction with persistent enlargement of the ovaries, uterine 
subinvolution and irregularity. hCG levels persist abnormally plateaued or get elevated after 
mole evacuation. Signs of non-postmolar choriocarcinoma are unspecific and commonly arise 
as the tumor invades the uterus or metastasizes to distant organs, leading to pulmonary, 
gastrointestinal and/or neurological symptoms. In these cases, elevated hCG levels are usually 
identified along with the discovery of metastasis (Lurain 2010). Pathologically, the diagnosis 
of choriocarcinoma can be made by curettage, evaluation of placental or hysterectomy 
specimens and by the biopsy of metastasis. 
Chemotherapy constitutes the standard treatment for GTN (Smith et al. 2005). Depending on 
staging, single or multiple-agent chemotherapy is chosen. Methotrexate or actinomycin D is 
usually administered in patients with nonmetastatic or low-risk GTN (Foulmann et al. 2006, 
Roberts and Lurain 1996, Osborne et al. 2011). Patients with high-risk metastatic GTN, 
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particularly those at high risk of therapy failure, are usually treated with a combination of 
drugs (Lurain et al. 2006, Escobar et al. 2003, Xiang et al. 2004). Response to treatment is 
evaluated by serum hCG levels every week. Nowadays, GTN constitute some of the most 
curable solid tumors, even in the presence of metastasis (Lurain 2010). 
 
 
1.4 – The JAK/STAT Signaling Pathway 
 
The Janus Kinase / Signal Transducers and Activators of Transcription (JAK/STAT) pathway 
is one of the main signaling mechanisms in mammals, used to transduce the signals of a broad 
spectrum of cytokines and growth factors (Rawlings et al. 2004). This pathway has been 
implicated in the transduction of a multitude of signals governing development and 
homeostasis, including cell proliferation, differentiation, migration and apoptosis (Bromberg 
2001). These events are essential for several physiological processes, such as immune 
regulation, hematopoiesis, adipogenesis, mammary gland development etc (Rawlings et al. 
2004). Predictably, dysfunction of the JAK signaling (aberrant activation or impaired 
regulation) has been associated with pathological conditions, such as erythrocytosis, 
inflammatory diseases and leukemias (Rawlings et al. 2004, Igaz et al. 2001). 
JAK/STAT activation occurs upon binding of specific ligands on cell surface, inducing 
multimerization of receptor subunits (which are bound as homo or heterodimers), whose 
cytoplasmic domains are associated with two tyrosine kinases - the Janus kinases (JAKs). The 
JAKs structure reveals two similar phosphate-transferring domains at it C-terminus, one with 
kinase activity and the other one with negative regulatory property. By the way, the name 
Janus Kinases derives from this “double-headed” structure, resembling the two-headed 
Roman mythological god Janus (Fitzgerald et al. 2010). 
After ligand binding promotes receptor multimerization and juxtaposition of the two receptor-
associated JAKs, these are brought into close proximity and activate each other through cross-
phosphorylation. Furthermore, the activated JAKs promote phosphorylation of additional 
targets, including inner substrates and specific cytoplasmic domains of the JAK-associated 
receptor (Fitzgerald et al. 2008). Among them, intracellular STATs are latent transcriptional 
factors residing in the cytoplasm and constitute a major substrate for JAKs phosphorylation. 
After binding to the phosphorylated receptor domains, the latent STATs in the vicinity of the 
activated JAKs are then phosphorylated by the latter and dissociate to form homo and 
heterodimers, which translocate to cell nucleus by the importin α-5 (also known as 
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nucleoprotein interactor 1) and the Ran nuclear import pathway. In the nucleus, these homo 
and heterodimers bind and manipulate the promoter regions of target genes, ultimately 
influencing their transcription (Rawlings et al. 2004). 
Furthermore, the JAK/STAT signaling pathway is modulated by negative regulators, such as 
the Protein Tyrosine Phosphatases (PTPs), the Suppressors of Cytokine Signaling (SOCS) and 
the Protein Inhibitors of Activated STATs (PIAS). Direct and indirect mechanisms lead to 
negative modulation of the JAK/STAT cascade. For example, some PTPs (such as the SHP-1) 
bind to phosphorylated JAKs and receptor domains, facilitating their dephosphorylation 
(Greenhalgh and Hilton 2001). Moreover, the SOCS negatively modulate the JAK/STAT 
pathway by different means, such as by inhibition of the JAK kinase activity upon direct 
binding to JAKs and JAKs-associated receptors. Some SOCS also can bind phosphotyrosines 
on receptor domains, what physically blocks them and prevents STATs recruitment. Some 
SOCS also facilitate ubiquitination of JAKs through interaction with the elongin BC complex 
and cullin 2, ultimately targeting the JAKs for proteasomal degradation (Alexander 2002). 
Interestingly, the expression of SOCS proteins is stimulated by the activated STATs, 
revealing a negative feed-back loop (Naka et al. 1997). Finally, the PIAS proteins bind to 
phosphorylated STAT dimers, preventing them to bind DNA (Rawlings et al. 2004). 
  
 
1.5 – Interleukin-6 (IL-6) 
 
Active IL-6 is a 184 amino acid-long cytokine, which is able to exert both pro- and anti-
inflammatory responses (Singh et al. 2011). Among others, it is synthesized by monocytes, 
macrophages, fibroblasts, T cells and endothelial cells. It is one of the most important 
mediators of the acute phase response, as well as an effector of the humoral immune response, 
inducing the syntheses of immunoglobulins. Besides inducing proliferation and differentiation 
of B- and T-cells, IL-6 is also involved in hematopoiesis, fever, osteoclast development, 
ACTH production etc (Aguzzi and Heikenwalder 2005, Moser and Willimann 2004, Ohsuzu 
2004, Gosain and Gamelli 2005, Heinrich et al. 1998).  
IL-6 activity is mediated by the binding of this cytokine to its type I cytokine receptor 
complex on cell surface, which is composed of the ligand-binding IL-6Rα chain and the 130 
kDa signal transducer protein (gp130) (Hibi et al. 1990, Yamasaki et al. 1988). The 
interaction leads to multimerization of these receptor subunits, activating the receptor. The 
activation promotes intracellular juxtaposition of the two receptor-associated JAKs, which are 
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brought into proximity and phosphorylate each other. IL-6 thus signals through the 
JAK/STAT pathway (Heinrich et al. 1998). IL-6 receptor is present on maternal and fetal 
tissues at the time of implantation, both in humans and in mice, suggesting a 
paracrine/autocrine role (Kojima et al. 1995, Tabibzadeh et al. 1995). 
IL-6 is mostly expressed in the endometrium (mainly in the epithelial glandular cells) in mid- 
to late-secretory phase (Singh et al. 2011, Tabibzadeh et al. 1995). The period of maximal 
expression coincides with the time of implantation window, inviting the hypotheses that this 
cytokine might play a role in the process of embryo invasion and implantation in early 
pregnancy. In fact, IL-6 has been demonstrated to induce proliferation and migration of 
trophoblast cells in vitro (Fitzgerald et al. 2005a), as well as to enhance the activity of 
metalloproteinases 2 and 9 (MMP-2 and MMP-9), which are involved in the degradation of 
extracellular matrix, thus enabling the trophoblast to invade the endometrium and reach 
maternal blood supply (Meisser et al. 1999). Furthermore, dysregulation of IL-6 expression 
seems to be associated with impairment of pregnancy. In these terms, IL-6 levels have been 
reported to be reduced during the mid-secretory phase in patients suffering from recurrent 
spontaneous abortion (von Wolff et al. 2000). In murine models, IL-6 deficiency correlates 
with reduced implantation sites and reduced fertility (Singh et al. 2011). In these models, even 
when implantation is achieved, blastocysts are found to be underdeveloped (Salamonsen et al. 
2000, Kopf et al. 1994). 
Besides its roles during early pregnancy, IL-6 has also been linked to cancer progression. This 
cytokine and the members of its family are usually observed in tumor microenvironments, 
where they promote the attraction of inflammatory cells, leading to an increased expression of 
proteases and proinvasive proteins (Sanz-Moreno et al. 2011, Coussens and Werb 2002). 
Additionally, IL-6 has been linked to metastatic progression in some malignancies, including 
ovarian, head and neck cancer, in which elevated levels of this cytokine in the serum have 
been associated to increased cell invasiveness (Nishino et al. 1998, Obata et al. 1997). In 
melanoma and colorectal cancer, IL-6 levels have been found extra-elevated in patients with 
advanced pathological stage, and preoperative measurement of serum IL-6 has thus been 
suggested as a potential biomarker of tumor metastases (Eldesoky et al. 2011).  
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1.6 – Leukemia Inhibitory Factor (LIF) 
 
Leukemia Inhibitory Factor (LIF) is a multifunctional 179 amino acid-long interleukin class 6 
cytokine initially discovered in the conditioned medium of rat liver cells (Omori et al. 1996). 
Its name comes from the ability of this molecule to induce the terminal differentiation of M1 
myeloid leukemic cells into macrophages (Tomida et al. 1984). 
This cytokine is expressed in different cell types, including neurons, ovarian stromal cells, 
breast, hepatocytes and kidney epithelial cells (Lass et al. 2001, Auernhammer and Melmed 
2000). Considered a Th2-type cytokine, LIF key functions point to mediation of inflammatory 
cell responses (Okahisa et al. 2010, Knight et al. 1999). Since its discovery, LIF has been 
proposed to be a multifunctional cytokine, playing a role in several physiological and 
pathological processes, including placentation in several species, trophoblast and human 
choriocarcinoma invasion, neural development, bone metabolism, inflammation, cancer 
cachexia, protection of photoreceptors from light damage etc (Burgi et al. 2009, Sims and 
Johnson 2012, Simamura et al. 2010, Kamohara et al. 2007, Fitzgerald et al. 2005b).  
On the cell surface, LIF binds to its specific low affinity receptor subunit (LIFR), triggering 
dimerization with it heterodimer, the transmembrane glycoprotein 130 (gp130), which is a 
STAT3-activating subunit common to all members of IL-6 receptor family. The binding 
forms a high affinity receptor and promotes juxtaposition of the receptor-associated Janus 
Kinases (JAKs), which reciprocally activate each other through cross-phosphorylation. In 
these terms, IL-6 type cytokines (among them LIF) have been reported to activate JAK1, 
JAK2 and TYK2 (Heinrich et al. 1998). The activation of JAKs leads in turn to 
phosphorylation of the cytokine receptors and of inner ligands, such as STAT3. Activated 
STAT3 then dissociate to form homo and heterodimers and translocate to cell nucleus, where 
they influence the transcription of target genes (Yamaoka et al. 2004). These events are 
summarized in Fig. 02. 
Finally, LIF signaling response is negatively modulated by the Suppressors of Cytokine 
Signaling (SOCS), whose action mechanism was previously described. Interestingly, SOCS3 
constitutes a STAT-induced protein which expression is stimulated by the LIF/JAK/STAT3 
pathway. In these terms, LIF suppresses its own effect through a negative feedback 
(Fitzgerald et al. 2008, Naka et al. 1997). 
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Fig. 02  JAK/STAT signal transduction pathway (Modified from Yamaoka, 2004) 
Cytokines of the IL-6 family bind to gp130 receptors, which are constitutively bound to two 
JAKs, leading to JAK cross-phosphorylation, what in turn leads to phosphorylation of the 
cytokine receptors. STAT proteins in the vicinity of these receptors are phosphorylated by 
activated JAKs, promoting STAT dimerization. STAT dimers translocate to cell nucleus, 
where they induce gene expression.  
 
 
LIF and Pregnancy 
 
LIF is assumed to facilitate embryo implantation and is considered indispensable during 
placentation (Paiva et al. 2009). Produced by human placenta and endometrium (especially in 
the glandular and luminal epithelium and in the endometrial stroma), its expression is 
maximally observed in the maternal-fetal interface at the time of implantation (Vogiagis et al. 
1996, Aghajanova et al. 2003, Bhatt et al. 1991). Furthermore, LIF mRNA is intensively 
expressed in decidual leukocytes present at the implantation site, suggesting a cross-talk 
between maternal leukocytes and the invading trophoblast via LIF (Sharkey et al. 1999). 
Cytokines such as LIF, IL-6, IL-11 
gp130 
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As blastocyst approximates to the endometrium, the latter expresses LIF at high levels, while 
the former produces LIF receptor, revealing a paracrine signaling (Cullinan et al. 1996, Tapia 
et al. 2008). LIF has been demonstrated to enhance extravillous trophoblast adherence to 
extracellular matrix components, such as fibronectin, vitronectin and laminin in vitro (Tapia 
et al. 2008). Furthermore, LIF increases the adhesion of human endometrial epithelial cells to 
collagen IV, present on the surface of blastocysts and first trimester trophoblast cells 
(Marwood et al. 2009, Shimomura et al. 2006, Kurosawa et al. 1985). After adhering to the 
endometrium, the blastocyst commences to express LIF mRNA itself, while LIF receptor is 
then expressed in the endometrium (Chen et al. 1999, Charnock-Jones et al. 1994). 
Additionally, an extra production of endometrial LIF is stimulated upon blastocyst adhesion, 
especially after the newly formed syncytiotrophoblast invades into the luminal epithelium and 
starts to express LIF-stimulating cytokines (such as IL-1) (Aghajanova 2004, Laird et al. 
2000). 
The LIF-induced changes in the adhesive properties of the endometrial epithelium have been 
considered essential for blastocyst attachment and constitutes a first step for subsequent cell 
migration and anchorage of the trophoblast in the maternal decidua (Dimitriadis et al. 2010). 
Over the last years it has been investigated which factors present in the maternal-fetal 
interface might regulate the expression of adhesion molecules, such as integrins and 
cadherins. Adhesion molecules are important for the interaction between cells and 
extracellular matrix and are thought to modulate trophoblast migration and invasion (Irving 
and Lala 1995, Burrows et al. 1996). For example, the cognate α5β1 integrin receptor present 
on the cell surface of extravillous trophoblast has been demonstrated to interact with 
fibronectin. This interaction influences the migratory activity of trophoblast cells, particularly 
where anchoring villi are formed (Ilic et al. 2001). 
In this context, and considering its maximal expression at the time of implantation, LIF has 
been investigated as a potential factor regulating the expression of adhesion molecules. 
However, its role in the modulation of integrins has found some controversy. As 
aforementioned, LIF has been demonstrated to increase the adhesion of extravillous 
trophoblast cells to fibronectin, vitronectin and laminin in vitro, particularly to the last (Tapia 
et al. 2008). LIF had been thought to modulate the expression of their respective integrin 
receptors on cell surface (such as α5β1 integrin receptor for fibronectin and α6β4 integrin 
receptor for laminin), but, interestingly, no influence on the expression of the integrin 
subunits α1, α5 and β1 has been demonstrated in trophoblast cells treated with LIF (using 
fluorescence-activated cell sorter analysis) (Sharkey et al. 1999). Moreover, LIF treatment has 
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been associated to a decreased mRNA expression of the β4 subunit in trophoblast cells, as 
verified by real-time RT-PCR analysis (Tapia et al. 2008). Taken together, these data suggest 
that the increased adhesion of trophoblast to these extracellular matrix components might 
involve the regulation of other integrin subunits rather than α1, α5, β1 and β4. It is also 
plausible that LIF might act in concert with other factors to regulate trophoblast integrins 
(Luo et al. 2007). Especially the LIF-induced inhibition of the β4 subunit has been focus of 
interest, since the differentiation of trophoblast cells of the cell column into an invasive 
phenotype has been linked to the downregulation of the integrin α6β4 (Aplin 1997, Damsky et 
al. 1992). This inhibition ultimately supports the hypotheses that LIF triggers the process of 
trophoblast differentiation towards an invasive phenotype. 
LIF has also been implicated in direct regulation of trophoblast invasion, since it may inhibit 
(Fitzgerald et al. 2005b) or stimulate the production of tissue inhibitors of metalloproteinases 
(TIMPs), which act as counterparts of matrix metalloproteinases (MMPs). MMPs are directly 
involved in the degradation of extracellular matrix, which is necessary to enable the 
trophoblast to invade the endometrium and reach maternal blood supply. Acting as 
counterpart, the TIMPs prevent excessive trophoblast invasion, ultimately contributing to a 
proper decidual invasion. This regulative effect supports previous studies demonstrating that 
LIF reduces gelatinase activity of trophoblast cells (Bischof et al. 1995) and suggests an 
overall inhibitory effect on trophoblast invasion. 
Finally, it must be considered that the role of LIF and its underlying signaling pathway have 
not been completely clarified. As many other cytokines, its exact mechanisms and possible 
crosstalks with other signaling cascades are still partially understood (Fitzgerald et al. 2008). 
Adequate trophoblast proliferation, migration and invasion are critical events for proper 
anchorage of the fetus to maternal endometrium and demand strict control of inter and 
intracellular signaling (Tapia et al. 2008, Genbacev et al. 1992). Dysregulation of the 
underlying mechanisms governing embryo implantation has been associated to adverse 
pregnancy outcome, leading in some cases to infertility (Dimitriadis et al. 2010). In this sense, 
LIF is considered critical for implantation, along with other cytokines, and disturbances in the 
fine regulation of its underlying JAK/STAT signaling pathway have been repeatedly 
associated to impairment of human and murine pregnancy (Dimitriadis and Menkhorst 2011). 
In this context, it is reasonable to think that studies investigating the role of LIF and its 
underlying signaling pathway might contribute to the better comprehension of the factors 
influencing embryo implantation and ultimately the factors necessary for a successful 
pregnancy outcome. 
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LIF, STAT3 and Cancer 
 
Signal Transducer and Activator 3 (STAT3) is a signal-transduction mediator that is activated 
by several cytokines and growth factors. STAT3 signaling pathway has been demonstrated to 
participate in the development of pluripotent cells and tumors (Levy and Lee 2002), playing a 
role, among others, in cell motility and protease regulation (Fitzgerald et al. 2008, Zhang et al. 
2002). Interestingly, dysregulation of STAT3 activity has been demonstrated to play a role in 
malignant cell transformation and tumor metastasis (Horiguchi et al. 2002). In these terms, 
aberrant STAT3 activity has been associated with the up-regulation of genes involved in cell 
cycle progression (e.g. c-myc) and apoptosis inhibition (e.g. mcl-1), posing the STAT3 
protein as a candidate with oncogenic potential (Fitzgerald et al. 2010). The aberrant activity 
leads to malignant cell behavior, which embraces hyperplasia, longevity and invasiveness 
(Epling-Burnette et al. 2001, Bromberg et al. 1999). Indeed, constitutively phosphorylated 
STAT3 has been identified in different malignancies, including brain, breast, prostate and 
skin cancer, in contrast to its transient nature in normal cells (Niu et al. 2002, Schaefer et al. 
2002, Dhir et al. 2002, Garcia et al. 2001).  
The factors influencing/inducing the aberrant activity of STAT3 in malignant cells have not 
been completely clarified. Considering that LIF directly signals through the JAK/STAT 
pathway, this cytokine poses as a potential modulator of STAT3 activity in tumor cells. As a 
matter of fact, LIF has been demonstrated to induce STAT3 activation in JEG-3 cells, a 
human choriocarcinoma cell line used as model for invasive, first trimester trophoblast. In 
these cells, LIF has been proposed to induce malignant behavior, stimulating cell proliferation 
and invasion in vitro (Fitzgerald et al. 2005b). Furthermore, the LIF-driven STAT3 activity 
has been related to the down-regulation of TIMP-1 (Fitzgerald et al. 2005b). As it is known, 
TIMP-1 possesses an anti-invasive activity, since it inhibits all metalloproteinases, including 
latent and active MMP-9 (Lala et al. 2002, Goldberg et al. 1992). TIMP-1 has also been 
linked to inhibition of metastasis (Bischof et al. 2001). In this sense, the LIF-induced down-
regulation of TIMP-1 has been suggested to induce the hyperinvasiveness of these cells 
(Fitzgerald et al. 2005b). On the other hand, LIF has also been assumed to induce an overall 
inhibitory effect on trophoblast invasion, as previously commented (Tapia et al. 2008, Bischof 
et al. 1995). Taken together, these data reveal that the influence of LIF on cell behavior has 
not been completely understood. Its role might even vary among cells from the pathological 
and physiological settings. In this sense, this work intended to better clarify the role of LIF 
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and the JAK/STAT signaling pathway in choriocarcinoma cell lines, which are considered 
models for studying trophoblast physiology.  
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2. Objectives 
 
The goal of this work was to clarify some of the components of the JAK/STAT pathway that 
are involved in the signal transduction of LIF in choriocarcinoma cell lines. With the aid of 
functional assays, it has also been investigated the effects of this cytokine on cell behavior. 
Finally, the same functional parameters have been analyzed after performing JAK1 knock-
down using the technique of RNA interference, in order to investigate if disturbances in the 
JAK/STAT signaling pathway might alter the behavior of these cells. 
 
Steps 
? Investigation of a possible correlation between LIF and IL-6 stimulation and STAT3 
phosphorylation in different choriocarcinoma cell lines by applying Western blots 
? Determination of which JAK isoforms are constitutively expressed in choriocarcinoma 
cells and placental tissues by applying Western blots and immunocytochemical studies 
? Determination of which JAK isoforms are phosphorylated upon LIF stimulation in 
choriocarcinoma cells by applying Western blot 
? Investigation of LIF effects on cell behavior by performing functional assays 
(proliferation, migration and invasion) 
? Establishment of an efficient JAK1 knock-down using the technique of RNA 
interference. To achieve this goal, different transfection reagents and siRNA 
concentrations have been tested 
? Evaluation of knock-down efficiency by means of Western blot 
? Evaluation of STAT3 phosphorylation in JAK1-silenced cells using Western blot 
? Investigation of the effects of JAK1 knock-down on cell behavior by performing 
functional assays (proliferation, migration and invasion) 
? Investigation of the effects of LIF stimulation on the proliferative, migratory and 
invasive behavior of JAK1-silenced cells 
 
Questionnaire 
? Do LIF and IL-6 induce tyrosine STAT3 phosphorylation in choriocarcinoma cell 
lines? 
? Are JAK1, JAK2 and JAK3 constitutively expressed in choriocarcinoma cells and 
placental tissues? 
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? Is LIF associated with the phosphorylation of these JAK isoforms in choriocarcinoma 
cells? 
? Does the reduced expression of JAK1 influence the LIF-induced STAT3 
phosphorylation in JAR cells? 
? Does LIF stimulation influence the proliferative, migratory and invasive behavior of 
choriocarcinoma cells? 
? Is the LIF-induced cell behavior altered in choriocarcinoma cells with reduced JAK1 
expression? 
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3. Material and Methods 
 
All experiments were performed in the Placenta Laboratory of the Department of Obstetrics, 
University Hospital Jena, under the supervision of Prof. Dr. med. Udo R. Markert. Many of 
the following methods were performed more than once. In this chapter, material and methods 
are briefly described in order to avoid unnecessary repetition and each method is correlated 
with its specific aim. Material origins and further specifications are presented in the last part 
of this work. 
 
 
3.1 – Cell Lines 
 
Human Choriocarcinoma Cell Lines JAR and JEG-3 
 
Many experiments in this work were performed using JAR and JEG-3 cells (Fig. 03 and 04), 
which are human choriocarcinoma cell lines (hCC) derived from first trimester trophoblast 
(Pattillo et al. 1971). Originally, JAR cells have been 
established from a placental trophoblastic tumor of a 
24-year-old Caucasian woman. JEG-3 cells have been 
isolated from a cerebral metastasis of a human 
gestational choriocarcinoma (Pattillo and Gey 1968, 
Kohler and Bridson 1971).  
JAR and JEG-3 cells have been chosen in this work 
because they are considered models for studying 
trophoblast physiology. These cells present several 
similarities with trophoblasts, such as the production of 
pregnancy related hormones, including ß-human 
chorionic gonadotropin, estrogen, progesterone, and 
placental lactogen. This is particularly interesting 
considering the difficulty in obtaining large amounts of 
freshly isolated trophoblast cells and the fact that 
primary trophoblasts have a short lifetime and hardly 
proliferate in vitro (Hiden et al. 2007). On the other hand, differences have also been 
described between JAR and JEG-3 cells, especially regarding their proliferative activity, 
 
 
Fig. 03 JEG-3 cells 
 
Fig. 04 JAR cells 
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invasive phenotype and degree of differentiation. JAR cells exhibit higher proliferation rate, 
higher invasive phenotype and are less differentiated in comparison to JEG-3 cells (Grummer 
et al. 1994). Doubling time lasts approximately 20 hours for JAR cells and 24 hours for JEG-3 
cells. In vitro, JAR and JEG-3 cells grow adherent in monolayer or in clusters, and the 
formation of cell aggregates are particularly common in JEG-3 cells   (http://www.dsmz.de). 
 
Hybrid Cell Lines ACH-3P and AC1-M59 
 
ACH-3P and AC1-M59 derive from the hybridization of human trophoblast cells with the 
choriocarcinoma cell line JEG-3.  
ACH-3P cells derive from the fusion of primary human first trimester trophoblasts (week 12 
of gestation) with AC1-1 cells, which are HGPRT-negative mutants of JEG-3 cells. ACH-3P 
cells express trophoblast markers (cytokeratin-7, matrix metalloproteinases, integrins etc) and 
possess invasive abilities and a transcriptome that closely resemble trophoblasts (Hiden et al. 
2007). These properties turn this immortalized cell line into a model of first trimester 
trophoblast. 
AC1-M59 cells are a non-tumorigenic subclone of ACH1-1 cells and derive from the somatic 
hybridization of AC1-1 cells with term extravillous trophoblast cells (Frank et al. 2000). 
These cells grow adherent in monolayers in vitro and present epithelioid morphology. 
Doubling time lasts approximately 50 hours (http://www.dsmz.de). 
 
 
3.2 – Cell Culture 
 
Cells were commercially obtained from ATCC (USA) and were maintained in 175 cm² flasks 
under standardized conditions (37°C, 5% CO2, humidified atmosphere) in DMEM 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 2% antimycotic-
antibiotic solution, composed of penicillin (100 IU/ml) and streptomycin (100 µg/ml) (AAS; 
Sigma, Germany). They were observed on a daily basis with an inverse microscope to ensure 
proper growth and absence of mycoplasma. 
Every two or three days, cells were trypsinized and incubated in new medium, in order to 
avoid disturbances in cell proliferation rate. All procedures were performed under sterile 
conditions. In these terms, cells were initially washed with PBS and were then incubated with 
500 µl trypsin for 5 min under standardized conditions. Upon the action of trypsin, the 
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adherent cells unstuck from well surface and could be diluted and/or used for experiments. 
For culture, they were adjusted to 105 cells/ml using a Neubauer chamber and were incubated 
in 2 ml supplemented DMEM medium. 
 
 
3.3 – Lymphocyte Isolation and Culture 
 
Lymphocytes were isolated using a Ficoll density gradient. Initially, peripheral venous blood 
of a healthy non-pregnant 25-year old donor was collected and diluted with PBS Buffer (1:1 
dilution). Sets of 7 ml diluted blood were carefully layered over 3 ml Ficoll 1,077 in 15 ml 
Falcon tubes and centrifuged for 20 min at 2500 U/min at room temperature with brake off. 
Upon this centrifugation, blood elements were separated according to their densities. 
Erythrocytes and granulocytes, which are denser than the other elements, accumulated at the 
bottom of the tube, forming a dark red 
layer. Laying on it, a transpartent layer was 
identified, corresponding to the Ficoll 
solution. Between the Ficoll and the upper 
yellow layer (composed of plasma and 
PBS), it was possible to identify a thin 
white layer, composed of peripheral 
lymphocytes (see Fig. 5). These were 
gently pipetted from the interface and were 
mixed with 5 ml RPMI, while erythrocytes 
and granulocytes were discarded. The 
solution with lymphocytes was submitted 
to two wash steps. In the first one, the solution was centrifuged for 8 min at 1500 U/min and 
the final supernatant was discarded. The pellet was resuspended in 5 ml RPMI and once more 
centrifuged, now for 5 min at 1500 U/min. The final supernatant was discarded and the 
remaining pellet was resuspended with 4 ml RPMI Medium (RPMI 1640 with 10% FBS). 
Cells were then distributed in 2 wells of a 6-well plate and cultured under standardized 
conditions (37°C in a 5% CO2 humidified atmosphere). 
Lymphocytes were then treated with Phytohemagglutinin (PHA) and submitted to cell lyses, 
as explained forewords, in order to obtain protein samples that could be used as positive 
control of JAK1, JAK2 and JAK3 expression in the experiments testing the presence of these 
kinases in choriocarcinoma cell lines. 
 
 
Fig. 05 Lymphocyte isolation 
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3.4 – Summary of Experiments 
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3.5 – Cell Stimulation 
 
Cell lines were treated with Leukemia Inhibitory Factor (LIF) or IL-6 for different periods. 
After adjusting cells to 1x105/ml with a Neubauer chamber, cells were incubated in wells of a 
6-well plate within 2 ml DMEM supplemented with 10% heat-inactivated FBS and with a 2% 
antimycotic-antibiotic solution, composed of penicillin (100 IU/ml) and streptomycin (100 
µg/ml). Cells were prepared in a sterile environment and were maintained under standardized 
conditions (37°C, 5% CO2, humidified atmosphere). One day before stimulation, this serum-
containing medium was substituted for the same volume of DMEM (2 ml) without FBS or 
antibiotics, in order to avoid cell stimulation by these factors. At the time of incubation with 
LIF or IL-6, the cells were approximately 70% confluent. After washing the cells with PBS 
and adding new 2 ml of pure DMEM, 2 µl of a 10 µg/ml LIF solution were added and gently 
mixed into each well. In these terms, a solution with approximately 10 ng/ml of LIF 
concentration was finally achieved. For IL-6 stimulation, 4 µl of a 10 µg/ml IL-6 solution 
were applied into each well, thus obtaining a solution with final concentration of 20 ng/ml. 
Cultured lymphocytes were stimulated with Phytohaemagglutinin (PHA) to a final 
concentration of 2 µg/ml. PHA is known to stimulate mitotic division of lymphocytes and 
facilitates chromosome analysis (when cells are arrested in metaphase by addition of 
colchicine). In addition, PHA treatment has been associated with stimulation of JAKs and 
STATs in human peripheral blood mononuclear cells (Kilic et al. 1999, Sanchez-Margalet and 
Martin-Romero 2001). PHA-treated lymphocytes were then submitted to cell lyses, and their 
protein supernatants were used as positive control in the experiments assessing the JAKs 
isoforms constitutively expressed in JEG-3 and JAR cells. 
 
 
3.6 – Cells Lysis and Protein Samples 
 
Cell Lyses 
 
Cell Lysis Buffer (CLB) was used to lyse cells under nondenaturing conditions, aiming to 
obtain protein samples that would be analyzed with Western blot. After treating cells 
according to the purpose of the experiment, each well was washed with 1 ml of PBS to 
remove residual media and given 100 µl of CLB (Cell Signaling) supplemented with 0.1% 
Protease Inhibitor Cocktail (Sigma). The plates were incubated on ice and cells were then 
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scraped and put into 1.5 ml labeled Eppendorf tubes, which were later submitted to 3 shock 
freezing cycles with liquid nitrogen. After frozen, the pellets were gently thawed in ice and 
then whirled in a vortex equipment. The products were centrifuged at 18,000 rpm, 4°C for 30 
min.  The final supernatants with proteins were carefully pipetted and stored at –80°C. 
 
Assessment of Protein Concentration 
 
Protein concentrations were assessed by the Bradford Method, which involves the binding of 
Coomassie Brilliant Blue G-250 dye to proteins. Coomassie forms complexes with cationic 
and nonpolar hydrophobic protein side chains, what in turn shifts its maximal absorption from 
465 nm to 595 nm (Lottspeich and Engels 2006). Protein concentration can thus be inferred 
measuring the absorption at 595 nm with a spectrophotometer. Experiments were performed 
as explained: 5 μl of protein lysates or standards (bovine serum albumin with known 
concentrations - BSA) were mixed with 995 μl of Bradford solution. After a 10-minute 
incubation period at room temperature in the dark, detection was performed at 595 nm by a 
spectrophotometer. A standard curve was drawn with the values obtained for BSA, and the 
protein concentration of the lysates was finally inferred. 
 
 
3.7 – Protein Analysis 
 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins according to their molecular 
weight, as seen in Fig. 06. With the use of sodium 
dodecyl sulfate (SDS), an anionic detergent, the 
secondary and non–disulfide–linked tertiary 
structures of proteins are denatured, leading them 
to linearize. As it is known, SDS overwhelms 
proteins with a negative charge, making them to 
migrate towards the positive pole when placed in 
an electric field 
(http://www.ruf.rice.edu/~bioslabs/studies/sds-page/denature.html). Denatured protein 
 
 
Fig. 06 SDS Electrophoresis 
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samples are then applied to polyacrylamide gel, a polymer of acrylamide monomers whose 
structure possesses a multitude of tunnels of different diameters. When the electrical field is 
applied, proteins start to move through these tunnels towards the anodes. Separation occurs as 
proteins with smaller molecular weight tend to migrate faster through the gel (Luttmann et al. 
2006). In this sense, proteins with the same molecular weight, even with completely different 
amino acid sequences, travel together in a mixed band. 
 
Electrophoresis and Western Blot 
 
After obtaining the samples and their respective concentrations, proteins were put in the same 
concentration (20-25 µg/ml) and volume (20-25 µl) and were run applied to 7.5% acrylamid 
gels for about 1 hour at 30 mA/gel in 500 ml Running Buffer. A protein ladder (dual color 
standard) was used to determine and control molecular weight. After proteins were 
fractionated by size, they were electrotransfered to a 10x10 cm nitrocellulose membrane for 
38 min at 240 mV (protein blotting), as demonstrated in 
Fig. 07. Binding depends on hydrophobe interactions and 
hydrogen bonds among proteins and the membrane 
(Lottspeich and Engels 2006).  
Membranes were then blocked in 25 ml of NetG for 30 
minutes at room temperature. After that, membranes were 
incubated overnight at 4°C with the primary antibody 
(e.g. Phospho-JAK1, JAK2 Antibody etc) at appropriate 
dilution (usually at 1:1000). On the next day, membranes 
were washed 3 times during 5 min with NetG and were 
then incubated for 1 hour with the second antibody 
(purified goat anti-rabbit IgG conjugated to horseradish 
peroxidase), diluted at 1:2000 in NetG. After washing 3 
times with Wash Buffer, each membrane was covered with plastic wrap and incubated with 1 
ml of LumiGLO® for 1 min at room temperature. In order to detect chemoluminescence, 
membranes were exposed to X-ray films in a dark chamber for different periods (10-35 min, 
depending on antibody) and films were finally developed for about 10 seconds. Another 
option to the X-ray exposure was the use of the MF-ChemiBIS 3.2 device, an automated 
documentation workstation that permits image acquisition (GelCapture). Software for image 
 
 
Fig. 07 Proteins on 
nitrocellulose membrane after 
electrotransference 
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analysis was used to detect and quantify protein bands (TotalLab TL100, version 2006, 
Nonlinear Dynamics Ltd.).  
 
3.8 – RNA Interference (RNAi) 
 
RNA interference (RNAi) is a method to knock down gene expression post-transcriptionally, 
permitting to investigate gene and protein function in different cell types (Fire et al. 1998, 
Wall and Shi 2003). It constitutes an evolutionary highly conserved process firstly observed 
in plants in the early 1990s, which was subsequently identified in fungus, invertebrates and 
mammals (Hannon 2002, Hamilton and Baulcombe 1999). In 1998 it was reported its 
underlying mechanism, in which double-stranded RNAs (dsRNA) were demonstrated to 
silence targeted genes in Caenorhabditis elegans (Fire et al. 1998). Since then, the process of 
gene silencing has been intensively investigated and regarded as a precious research tool, by 
which specific genes can be shut down and their role in several cellular processes can be 
analyzed. In humans, RNAi has been demonstrated to play a role in maintenance of genome 
integrity, cell defense against viral infection and regulation of gene expression (Sioud 2005). 
In cell research, traditionally long dsRNAs are delivered into the cell by lipid-mediated 
transfection or by viral-mediated transduction, depending on cell type and desired knock-
down period (transient or stable). The dsRNA is then cleaved intracellularly by the enzyme 
Dicer, an ATP-dependent ribonuclease III enzyme with helicase activity (Bernstein et al. 
2001). The dsRNA is processed into short fragments of 20-25 base pairs (sense and antisense 
strands) with 2-nucleotide 3'-overhangs and 5'-phosphorylated terminus, known as small 
interfering RNAs (siRNA) (Bernstein et al. 2001, Hutvagner and Zamore 2002). Subsequent 
to unwinding, the sense strand is cleaved and degraded, whereas the antisense strand is 
incorporated by the RNA-induced silencing complex (RISC), which detains endonuclease, 
exonuclease, helicase and homology-searching domains (Sledz and Williams 2005, Hannon 
2002).  
After incorporation, complementary sequences in mRNA molecules are then screened by 
these complexes. When paired, the targeted mRNA is cleaved by argonaute (a catalytic 
component of RISC) into portions that cannot be translated (Zeng et al. 2003). The 
mechanism of RNA interference is summarized in Fig. 08. 
Instead of using long dsRNAs, which have been reported to activate the innate immune 
response in mammalian cells (Williams 1999), it is also possible to achieve RNAi by 
transfection of synthesized 21-23 base pair siRNA duplexes. These duplexes mimic the 
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products originated by the action of Dicer on dsRNAs. After delivery in the cell, the sense and 
antisense strands of siRNA duplexes are processed similarly to dsRNAs. The antisense strand 
is incorporated by RISC and pairs with targeted mRNAs, while the sense strand is degraded 
(Elbashir et al. 2001, Caplen et al. 2001).Additionally, RNAi can be triggered by synthetic 
siRNAs, as well as by microRNAs (miRNAs), which are physiologically transcribed from the 
genome. As previously described, RNAi permits the post-transcriptional suppression of 
specific genes, ultimately contributing to a better comprehension of the components necessary 
for particular processes, such as cell division, migration and invasion.  
 
 
Fig. 08 Mechanism of RNA interference (Modified from Dykxhoorn 2003) 
Long double-stranded RNA (dsRNA) is digested by Dicer in siRNAs, which are then uptaken 
by RISC. Optionally, synthesized siRNA duplexes, which  mimic the products originated by 
the action of Dicer on dsRNAs, may be delivered into the cell by transfection The single-
stranded antisense strand helps RISC to find the target mRNA, culminating in specific mRNA 
cleavage and post-transcriptional gene silencing (Dykxhoorn et al. 2003). 
 
siRNA duplex 
sduplex transfection 
 
mRNA cleavage 
siRNA-mediated target recognition 
RISC activation 
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Oligonucleotide Annealing 
 
In order to obtain double-stranded RNAs (dsRNAs), designed to target JAK1, the same 
amount of single sense and anti-sense strands were diluted in nuclease-free water and were 
put together in 5x Annealing buffer, finally obtaining a mixture at a final concentration of 10 
µM. This mixture was then incubated for 1 min at 95° C and subsequently for 1 h at 37° C. 
This process facilitates single RNA strands to pair by hydrogen bonds to their complementary 
sequences, forming double-stranded oligonucleotides. Annealed oligonucleotides were then 
aliquoted and stored at -20° C. 
 
Cell Transfection 
 
After entering the cell, the dsRNA can be degraded by dicer into siRNA, which will 
ultimately promote specific gene silencing. But before achieving the intracellular space, the 
negatively charged dsRNA must pass across the lipid bilayered cell membrane. Several 
mechanisms have been developed to promote the dsRNA uptake into the cell, a process 
usually referred to as cell transfection and that has been considered a crucial step for the 
subsequent gene silencing. Two reagents have been used in this work for transfection – 
Oligofectamine and Nanofectin. 
 
Transfection with Oligofectamine 
 
Oligofectamine is a cationic lipid-based reagent that spontaneously interacts with 
oligonucleotides, forming transfection complexes that facilitate the delivery of antisense 
oligonucleotides and dsRNAs into the cells (Li et al. 2002, Elbashir et al. 
2001)Oligofectamine™ Reagent datasheet 2004). All experiments using Oligofectamine were 
performed according to the Protocol for siRNA Transfection of the Placenta Laboratory. Cells 
were initially trypsinized and split about 30-40% confluent in 6-well plates in 2 ml of DMEM 
supplemented with 10% heat-inactivated FBS and 2% antimycotic-antibiotic solution. After 
overnight incubation under standardized conditions (37°C, 5% CO2, humidified atmosphere), 
the medium was aspirated and cells were washed with 500 µl of OPTIMEM. 800 µl of fresh 
OPTIMEM were then added to each well, and the “Oligos-Oligofectamine” mix was prepared 
as follows: a solution composed of 175 µl of OPTIMEM and 10 µl of Oligos (i.e. Scrambled 
sequence or JAK1 siRNA, from 10 µg/µl aliquots) was mixed with 11 µl of OPTIMEM and 4 
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µl of Oligofectamine. After a 20-minute incubation period at room temperature, this mix was 
carefully added to the cells, which were subsequently incubated for 4 hours under 
standardized conditions. In order to stop RNAi transfection, 500 µl of DMEM containing 
30% of heat-inactivated FBS and no antibiotic were given to each well. According to their 
purpose, cells were incubated for different periods (24 or 48h) and stimulated with LIF or not. 
Finally the cells were submitted to lyses as previously described, and lysates were used in 
electrophoresis and Western Blot. Scrambled siRNA with a non-genomic sequence was used 
as control to verify possible unspecific effects intrinsic to transfection. 
 
Transfection with Nanofectin 
 
Nanofectin is a transfection reagent based on nanotechnology. It consists of nanoparticle-
based compounds and small positively charged carrier molecules, which are supposed to 
facilitate siRNA binding and transference into mammalian cells (Nanofectin & Co datasheet). 
In this work, all experiments were performed according to the Protocol for siRNA 
Transfection of the Placenta Laboratory. Cells were initially trypsinized and split about 50% 
confluent in 6-well plates in 2 ml of DMEM supplemented with 10% heat-inactivated FBS 
and 2% antimycotic-antibiotic solution. After overnight incubation under standardized 
conditions (37°C, 5% CO2, humidified atmosphere), the medium was aspirated and cells were 
washed with 500 µl of OPTIMEM. 800 µl of fresh OPTIMEM (without serum or antibiotic) 
were then added to each well, and the Nanofectin mix was prepared. Considering that 
Nanofectin-mediated transfection had not been tested so far for JAK1 gene silencing in our 
laboratory, four mixtures with different concentrations of JAK1 siRNA and Nanofectin have 
been prepared, aiming to obtain a mix with optimal silencing rates. In this sense, solutions 
composed of 60 µl of OPTIMEM and 6 or 9 µl of JAK1 siRNA (from 10 µg/µl aliquots) were 
mixed with 60 µl of OPTIMEM and 10 or 15 µl of Nanofectin. The mix containing the 
Scrambled siRNA sequence was prepared as follows: a solution composed of 60 µl of 
OPTIMEM and 6 µl of Scrambled siRNA (from 10 µg/µl aliquots) was mixed with 60 µl of 
OPTIMEM and 10 µl of Nanofectin. After a 20-minute incubation period at room 
temperature, the resultant mixtures were carefully added to the cells, which were subsequently 
incubated for 4 hours under standardized conditions. In order to stop siRNA transfection, 500 
µl of DMEM containing 30% of heat-inactivated FBS and no antibiotic were given to each 
well. After a 24-hour incubation period, cells were finally submitted to lyses as previously 
described, and lysates were used for Western Blot. Scrambled siRNA, which contains a non-
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genomic sequence, was used as control to verify possible unspecific effects intrinsic to 
transfection. 
 
 
3.9 – Functional Assays 
 
In order to test the hypotheses that Leukemia Inhibitory Factor (LIF) modifies functional 
parameters of JAR cells, it was performed a set of experiments assessing the proliferative, 
migratory and invasive behavior of these cells after LIF treatment, as explained as next. 
Results were compared with the behavior of untreated cells. Furthermore, it was investigated 
if the disruption of Janus kinase 1 (JAK1) through RNA interference might alter cell 
behavior. In this context, JAK1 knock-down was performed using a specific siRNA sequence 
and a new set of functional assays was conducted. Finally, JAK1-silenced cells were 
stimulated with LIF to verify if this cytokine might modify cell behavior, even after 
disrupting a component of its signaling cascade. 
All experiments started with about 30,000 cells (value extrapolated after cell counting with a 
Neubauer chamber), which were seeded into individual wells of a 24-well plate (Fig. 09). In 
those experiments in which LIF was used, cells were stimulated throughout the cultivation 
period (24 hours) at a final concentration of 10 ng/ml. Final cell counting was performed by 
flow cytometry. 
 
Preparation of in vitro Cell Proliferation Assay 
 
Cells were initially prepared according to the specific goal of the experiment (for example, in 
the experiments testing the behavior of JAK1-silenced cells, RNAi was initially performed 
using a specific siRNA sequence and Oligofectamine for transfection, as previously 
described). Cells were then trypsinized and counted with the use of a Neubauer chamber. 
30,000 cells were commenced into wells of a 24-well plate in a final volume of 700 µl of 
DMEM with nor serum or antibiotic. When possible effects of LIF were tested, LIF was 
applied into each well at a final concentration of 10 ng/ml. Plates were incubated during 24 
hours under standardized conditions (37°C, 5% CO2, humidified atmosphere). On the next 
day, the supernatant was initially transferred into FACS tubes. Each well was then washed 
with 200 µl of PBS, which was also collected in the tubes. Each well was trypsinized (200 µl 
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of Trypsin), and washed once more with new 200 µl of PBS. All these solutions were added 
into the FACS tubes for subsequent assessment of proliferation by analysis of cell number. 
 
Preparation of in vitro Cell Migration Assay 
 
Firstly the cells were prepared according to the specific goal of the experiment (e.g. JAK1 
knock-down). They were then trypsinized and counted with the use of a counting chamber. 
About 30,000 cells were put in a final volume of 300 µl of serum-free DMEM and were 
applied onto filters of 24-well plate size (upper well). Each filter was laid down on a well of 
the 24-well plate (lower well) previously filled with 400 µl of DMEM without FBS or 
antibiotics. When possible effects of LIF 
stimulation were tested, LIF was applied and 
gently mixed into the lower well at a final 
concentration of 10 ng/ml. The plate was 
incubated during 24 hours under standardized 
conditions (37°C, 5% CO2, humidified 
atmosphere). On the next day, the medium 
beyond the filter was initially transferred into 
FACS tubes. Each well was then washed with 
200 µl of PBS, which was also collected in 
the tubes. Each well and the respective 
downside of the filter were trypsinized (200 
µl of Trypsin), and washed once more with 
new 200 µl of PBS. All these solutions were 
added into the FACS tubes for subsequent 
counting. 
 
Preparation of in vitro Cell Invasion Assay 
 
Initially the MatrigelTM solution (1:10 dilution in pure DMEM media) was prepared and 100 
µl were applied onto filters of 24-well plate size, and let to dry in incubator for 4 hours. The 
remaining liquid was carefully pipetted. The cells that had been previously prepared 
according to the specific goal of the experiment (e.g. JAK1 knock-down) were trypsinized 
and counted with the use of a counting chamber. 30,000 cells were then put in a final volume 
 
 
Fig. 09 Proliferation (P), migration (M) and 
invasion (I) assays performed in duplicate. 
Note that filters have been placed on wells 
for migration and invasion tests (2nd, 3rd, 5th 
and 6th columns) 
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of 300 µl of serum-free DMEM and were applied onto the gel. Each filter containing the gel 
and the cells was laid down on a well (of the 24-well plate) previously filled with 400 µl of 
DMEM with no supplements. When possible effects of LIF stimulation were tested, this 
cytokine was applied and gently mixed on the solution on the gel in a final concentration of 
10 ng/ml. The plate was incubated during 24 hours under standardized conditions (37°C, 5% 
CO2, humidified atmosphere). On the next day, the medium beyond the filter was initially 
transferred into FACS tubes. Each well was then washed with 200 µl of PBS, which was also 
collected in the tubes. Each well and the respective downside of the filter were trypsinized 
(200 µl of Trypsin), and washed once more with new 200 µl of PBS. All these solutions were 
added into FACS tubes for analysis. 
 
 
3.10 – Flow Cytometry 
 
This technique was used to count cells in the proliferation, migration and invasion assays. The 
flow cytometer possess a fluidic system that forces a sample of cells to pass in a single cell 
stream through a laser beam, in a way that each cell scatters light or emits fluorescence. An 
optic system composed of several forward and perpendicular scatters and fluorescent 
detectors collect these light signals, which are then converted into numerical values that can 
be analyzed by a designed software. The parameters measured by this optic system permits 
deriving data about the chemical and physical structure of individual cells, which can be 
finally counted and characterized. Furthermore, monoclonal antibodies directed toward 
surface antigens and conjugated with fluorescent molecules can be used to label or tag cells. 
Fluorescent signals emitted when the cells are funneled to the laser beam are in the same way 
collected by the optic system, making cell sorting possible (fluorescence activated cell 
sorting). Several parameters may be assessed by flow cytometry, including cellular 
phenotype, DNA and RNA content, cell viability and granularity etc (BD Biosciences 
datasheet 2008). 
In the set of experiments, the tubes of the flow cytometer were prepared as described in in 
vitro cell proliferation, migration and invasion assays. Prior to analysis, a mixture of 100 µl of 
PBS and Polystyrene Beads (TrueCount Beads) was added to each tube. Bead number was 
also quantified during the flow cytometry tests. This parallel bead counting served as control, 
assuring the cytometer to stop cell counting when a predetermined number of beads had been 
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reached. Beads and cells were differentiated by the cytometer through their different size, as 
evidenced in the dot plot graphic in Fig 10. 
 
 
Fig. 10 Flow Cytometry Dot-Plot 
Flow Cytometry was used to quantify JAR cells in the functional assays. Predetermined 
volumes of cell suspension were incubated with polystyrene beads. Cells and beads were 
differentiated by the Flow Cytometer according to their sizes. Cell counting has stopped when 
a predetermined number of beads had been detected, serving as control. (FSC-H = Forward 
Scatter; SSC-H = Sideward Scatter)  
 
 
3.11 – Immunocytochemistry  
 
Immunocytochemical studies were performed to identify the constitutive expression of Janus 
Kinases 1, 2 and 3 in JAR, JEG-3 and human placental cells. Placentary tissues have been 
obtained from a healthy woman who underwent elective abortion in the 11th week of 
pregnancy. These tissues were kindly prepared by Maja Weber (Ph.D. student). 
Immunocytochemical staining protocol was defined by Maja Weber and Prof. Sebastian San 
Martin. 
Placental tissues were initially washed with PBS and incubated during 48 hours at 4°C in 4% 
Paraformaldehyde in 0.1 M PBS for cell fixation. Cells were washed with 0.1 M glycine in 
PBS overnight at 4°C. On the next day they were submitted to an ethanol-based hydration, in 
Beads 
JAR cells 
Dead cells and 
fragments 
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which cells were incubated with crescent concentrations of ethanol (50%, 70%, 95% and 
100% during 30 min for each concentration) at room temperature. Incubation with 95% and 
100% ethanol was repeated three times. After washing ethanol three times (15 min each) with 
Xylol, the tissue was imbibed with paraffin (Histosec) four times (30 min each) at 56-60°C. 5 
µm thick tissue slices were obtained by a microtome. These slices were laid down on 
microscope slides and were stored at 4°C. In order to deparaffinize and rehydrate the samples, 
slides were incubated twice in Xylol for 30 min each time, followed by ethanol incubation 
(twice in 100% ethanol for 30 min each time, then once in 95% for 30 min and once more in 
70% ethanol for 30 min) and finally in distilled water for 15 min. Subsequently the tissue 
slices were incubated in 10 mM citrate sodium buffer (pH 6.0) for 10 min at 95°C and cooled 
down during 30 min in the same buffer for antigenic retrieval. They were then washed three 
times with distilled water for 5 min each time, followed by wash with 0.1M PBS twice for 15 
min. For unspecific binding blocking the slides were incubated during 1 hour in 5% goat 
serum diluted in 0.3% PBS/Tween20 at room temperature in a humid chamber. Final blocking 
was obtained with incubation in Cas-Block (Zymed) for 10 min. The selected first antibody 
(Jak1, Jak2 or Jak3 antibody) diluted 1:100 in PBS/Tween20 was then applied on the fixed 
tissue and slides were incubated overnight at 4°C. On the next day, the slides were washed 
tree times with 0.1 M PBS for 5 minutes and incubated with the second antibody (Anti-Rabbit 
IgG, which is conjugated to Fluorochrome Cy3) during 1 hour in a 1:400 0.1 M PBS solution 
at room temperature. Slides were washed three times with 0.1 M PBS and the cell nucleus 
were mounted with 1.5 µg/ml DAPI medium (4,6-Diamidino-2-phenylindole-
dihydrochloride). A cover slip was laid on each slide, which was finally sealed with nail 
enamel (Yves Saint Laurent Paris, France). Slides were stored at 4° C and a fluorescence 
microscope was used for analysis. 
JAR and JEG-3 cells suspended in DMEM were separately applied onto Poly-L-Lysine 
covered microscope slides after 1:1000 dilution in GBSS (Gey’s Balanced Salt Solution). The 
slides were incubated overnight under standardized conditions (37°C, 5% CO2, humidified 
atmosphere) and applied on the next day to 4% Paraformaldehyde during 1 hour for cellular 
fixation. After washing twice with 0.1 M PBS during 15 minutes, the slides rested during 1 
hour in 5% goat serum diluted in 0.3% PBS/Tween20 at room temperature in a humid 
chamber. Final blocking to avoid unspecific binding was reached with incubation in Cas-
Block (Zymed) for 10 min. The selected first antibody (Jak1, Jak2 or Jak3 antibody) diluted 
1:100 in PBS/Tween20 was then applied on the fixed cells and slides were incubated 
overnight at 4°C. On the next day, the slides were washed tree times with 0.1 M PBS for 5 
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minutes and incubated with the second antibody (Anti-Rabbit IgG) in a 1:400 0.1 M PBS 
solution during 1 hour at room temperature. Slides were washed three times with 0.1 M PBS 
and the cell nucleus were mounted with 1.5 µg/ml DAPI medium (4,6-Diamidino-2-
phenylindole-dihydrochloride). A cover slip was laid on each slide, which was finally sealed 
with nail enamel. Slides were stored at 4° C until analysis with fluorescence microscope. 
 
 
3.12 – Documentation and Significance Tests 
 
Western blot pictures were obtained using the Gel Documentation System, composed of the 
equipment MF-ChemiBIS 3.2 and the software Gel-Capture. Quantitative analysis of Western 
blot bands was performed using the softwares Gel-Capture and TotalLab 100 Version 2006 
(Nonlinear Dynamics Ltd). 
Flow cytometry experiments were conducted using the equipment FACSCalibur (BD 
Bioscience). Their qualitative and quantitative results were assessed by the Cell Quest Pro 
Program. 
Bars, graphics, tables and statistical analysis were prepared, calculated and/or presented using 
Microsoft Excel.  
Error bars indicate, according to the experiment, standard deviation (S.D.) or standard error 
(S.E.), which was calculated to consider the range of error factors. Significance was 
determined by Student’s T-test, which calculates the probability (p) of two data sets to be not 
significantly different from each other. The difference was considered significant when p < 
0.05.  
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4. Results 
 
 
4.1 – LIF and IL-6 Influence on STAT3 Phosphorylation 
 
In order to investigate if Leukemia Inhibitory Factor (LIF) and Interleukin-6 (IL-6) are 
associated with the phosphorylation of tyrosine STAT3, different cell lines (JEG-3, JAR, 
AC1-M59 and ACH-3P) were cultured and stimulated with LIF or IL-6 for different periods 
at final concentrations of 10 ng/ml and 20 ng/ml respectively. At the time of LIF or IL-6 
treatment, cells were approximately 70% confluent in 6-well plates filled with 2 ml of pure 
DMEM. After each desired stimulation time has been reached, cell lyses and Western blot 
were performed for protein analysis. 
The figure below (Fig. 11.1) evidences STAT3 phosphorylation using Western blot. As it can 
be observed, very intense bands of phosphorylated tyrosine 705 STAT3 (Ph-STAT3) were 
verified in cell groups stimulated with LIF. Practically no bands for Ph-STAT3 are seen in 
respective control groups and cells that were treated with IL-6. ß-Actin was used as control. 
Cells were stimulated for 10 min (except Control group). These findings are supported by the 
quantification of Western blot bands, seen as next (Fig. 11.2). Values were normalized to 
control of each cell group, which value was set as 100%. In the three cell groups, stimulation 
with LIF was associated with a significant increase of phosphorylated STAT3 (p<0.05, n=4). 
 
Control IL-6 LIF
JEG-3 AC1-M59 ACH-3P
Control IL-6 LIF Control IL-6 LIF
ß-Actin
Ph-Stat3 
 
 
Fig. 11.1   STAT3 tyrosine phosphorylation after IL-6 and LIF stimulation in JEG-3, 
AC1-M59 and ACH-3P cells (Western blot bands) (n=4) 
Cell groups: Control (non-treated cells), IL-6 (IL-6 treated cells), LIF (LIF-treated cells). 
Ph-STAT3 (Tyr705): phosphorylated tyrosine 705 STAT3. 
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Fig. 11.2   STAT3 tyrosine phosphorylation after LIF or IL-6 stimulation in JEG-3, 
AC1-M59 and ACH-3P cells (quantification of Western blot bands) 
Cell groups: Control (non-treated cells), IL-6 (IL-6 treated cells), LIF (LIF-treated cells) 
 
 
Subsequently, STAT3 tyrosine phosphorylation was assessed in JEG-3 and JAR cells after 
different periods of LIF stimulation. Treatment length ranged from 5 to 40 min in JEG-3 cells 
and from 02 to 10 min in JAR cells. As demonstrated in Fig. 12, phosphorylated STAT3 was 
detected during the whole experiment after LIF stimulation in JEG-3 and JAR cells. ß-Actin 
was used as reference control. 
 
JARJEG-3
Control 02 min 05 min 10 min
Ph-Stat3 
ß-Actin
Control 05 min 10 min 15 min 20 min 40 min  
Fig. 12   STAT3 tyrosine phosphorylation induced by LIF stimulation in JEG-3 and 
JAR cells  (n=2) 
Cell groups: Control (non-treated cells). 05 min, 10 min, 15 min, 20min and 40 (LIF-treated 
cells. Treatment length ranged from 5 to 40 minutes). 
Ph-STAT3: phosphorylated tyrosine 705 STAT3. 
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The Western blot bands below (Fig. 13.1) demonstrate another evidence of STAT3 
phosphorylation. In these experiments, JEG-3 and JAR cells were treated with LIF for 
different periods (treatment length ranging from 2 to 10 min), except Control group. 
Phosphorylated and non-phosphorylated STAT3 were assessed. As it can be observed, 
phosphorylated STAT3 bands (Ph-STAT3) get more intense with longer periods of LIF 
stimulation. On the other hand, the expression of non-phosphorylated STAT3 becomes 
progressively reduced in both cell groups, suggesting that LIF induces the conversion of the 
non-phosphorylated STAT3 into it activated form. The quantification of these Western blot 
bands reinforces this evidence, as seen in Fig. 13.2. Values were normalized to STAT3 
expression (each value derives from the ratio Ph-STAT3 / STAT3 using the values obtained 
from Western blot bands quantification). Values of control groups (in which cells had not 
been incubated with LIF) were set as 100%. With longer periods of LIF treatment, the ratio 
above indicates that STAT3 is being progressively converted into its phosphorylated form. 
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Ph-STAT3 
JARJEG-3
STAT3
 
 
Fig. 13.1   STAT3 phosphorylation (Tyr705) after LIF stimulation in JEG-3 and JAR 
cells (n=2) 
Cell groups: Control (non-treated cells). 2 min, 5 min and 10 min (LIF-treated cells. 
Treatment length ranged from 2 min to 10 min). 
Ph-STAT3: phosphorylated tyrosine 705 STAT3; STAT3: non-phosphorylated STAT3. 
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Fig. 13.2   STAT3 phosphorylation (Tyr705) after LIF stimulation in JEG-3 and JAR 
cells (quantification of Western blot bands) 
Cell groups: Control (non-treated cells). 2 min, 5 min and 10 min (LIF-treated cells. 
Treatment length ranged from 2 min to 10 min). 
 
 
 
4.2 – Constitutive Expression of Janus Kinases in JEG-3 and JAR cells and Their 
Possible Involvement in the LIF-Induced STAT3 Tyrosine Phosphorylation 
 
Different Janus Kinases (JAK1, JAK2 and JAK3) were initially assessed in JEG-3 and JAR 
cells, aiming to know which isoforms might be constitutively expressed in these cells. In 
order to investigate if LIF is associated with the phosphorylation of these JAK isoforms, cells 
were stimulated with LIF for different periods at a final concentration of 10 ng/ml. At the 
time of LIF incubation, cells were approximately 70% confluent in 6-well plates filled with 2 
ml of pure DMEM. After each desired stimulation time was reached (ranging from 2 to 10 
min), cell lyses and Western blot were performed. 
The next figure (Fig. 14) shows Western blot bands obtained from experiments assessing the 
constitutive isoforms of Janus Kinases expressed in JEG-3 and JAR cells. The rectangles 
show the bands obtained in control groups (i.e. cells that had not been stimulated with any 
cytokine). Lymphocytes stimulated with PHA (Lymph + PHA) were used as positive control 
for the three tested JAKs isoforms. ß-Actin was used as reference control. Comparing the red 
rectangles, it can be observed that JAK1 is constitutively expressed in JAR cells, but not in 
JEG-3 cells (or maximally to a very marginal degree). Taken the orange rectangles, an intense 
signal of JAK2 antibody can be seen in JAR cells, but just a very slight signal in JEG-3 cells. 
Considering the yellow rectangles, it can be observed that JAK3 is not constitutively 
expressed in these cells. Taken these data together, it can be inferred that JEG-3 cells express 
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mainly JAK2 constitutively, but only to a marginal degree, whereas JAR cells constitutively 
express JAK1 and JAK2. 
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Fig. 14 Constitutive expression of JAK1, JAK2 and JAK3 in JEG-3 and JAR cells (n=3) 
Cell groups: Lymph + PHA (lymphocytes stimulated with PHA); Control (non-treated cells); 
2 min, 5 min and 10 min (LIF-treated cells. Treatment length ranged from 2 to 10 minutes). 
JAK1: constitutively expressed JAK1; JAK2: constitutively expressed JAK2, JAK3: 
constitutively expressed JAK3 
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4.3 – Constitutive Expression of Janus Kinases in Choriocarcinoma Cell Lines and 
Placental Tissues Assessed by Immunocytochemistry 
 
Immunocytochemical Analysis in JEG-3 and JAR Cells 
 
Immunocytochemical studies were performed to proof the results obtained by Western blot, 
concerning the JAK isoforms constitutively expressed in JEG-3 and JAR cells. After 24-hour 
incubation, cells were fixed with paraformaldehyde and were then maintained with the first 
(JAK1, JAK2 or JAK3) and second antibodies, according to protocol. Images are seen below 
(Fig. 15 and 16). 
The images obtained from the immunocytochemical experiments evidence, in most cases, 
similarities with the results obtained by Western blot. In JEG-3 cells, JAK2 antibody 
promoted an intense and diffuse staining of cell membrane and cytoplasm. JAK1 staining was 
practically negligible, while JAK3 staining was absent. In JAR cells, all JAK antibodies 
correlated with staining of cell membrane and cytoplasm. However, staining was much more 
evident for JAK1, not so intense for JAK2 and practically insignificant for JAK3. 
 
 
JEG-3 Cells  
  
Fig. 15 Constitutive expression of JAK1, JAK2 and JAK3 in JEG-3 cells (n = 1) 
a = cells in phase contrast imaging; b = cell nucleus (DAPI stain); c = JAK isoform staining; d 
= addition of b + c. Magnification (x 200). 
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JAR Cells 
 
Fig. 16 Constitutive expression of JAK1, JAK2 and JAK3 in JAR cells (n = 1) 
a = cells in phase contrast imaging; b = cell nucleus (DAPI stain); c = JAK isoform staining; d 
= addition of b + c. Magnification (x 200). 
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Immunocytochemical Analysis in Placental Tissues  
 
Immunocytochemical analysis was performed to assess which JAK isoforms are 
constitutively expressed in placental tissues. Samples were obtained from the placenta of a 
healthy woman undergoing elective abortion during the 11th week of pregnancy. JAK 
expression was then compared to that observed in choriocarcinoma cell lines. After 24-hour 
incubation, villous and extravillous trophoblast cells were fixed with paraformaldehyde and 
were then maintained with the first (JAK1, JAK2 or JAK3) and second antibodies, according 
to protocol. Images are seen below (Fig. 17 and 18). 
 
 
Fig. 17 Constitutive expression of JAK1, JAK2 and JAK3 in fist trimester villous 
trophoblast cells (n=1) 
Immunocytochemical analysis identified strong signals of JAK1 and JAK2 in the periphery of 
placental villi, mostly in the cytoplasm. Practically no JAK3 staining was verified. 
Magnification (x 100). 
 
 
Fig. 18 Constitutive expression of JAK1, JAK2 and JAK3 in first trimester extravillous 
trophoblast cells (n=1) 
Immunocytochemical analysis revealed just a marginal degree of JAK1, JAK2 and JAK3 
staining in extravillous trophoblast cells, mostly in the cytoplasm. Magnification (x 100). 
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4.4 – LIF-Induced Janus Kinases Phosphorylation in JEG-3 and JAR cells 
 
Janus Kinase 1 
 
The Western blot bands below (Fig. 19) derive from experiments in which JEG-3 and JAR 
cells were incubated with LIF during different periods (ranging from 2 to 10 min). 
Phosphorylated JAK1 (Ph-JAK1) and constitutive JAK1 expression (JAK1) were assessed. ß-
Actin was used as reference control. In JEG-3 cells, practically no bands are observed for 
JAK1, while a very slight signal is identified for Ph-JAK1, although its intensity seems not to 
vary with the period of treatment. These bands have been considered as unspecific signals. In 
JAR cells, LIF stimulation correlated with a fast and transitory increase of the phosphorylated 
form of JAK1 (see upper bands), while the signals of its non-phosphorylated form became 
slighter with longer periods of LIF stimulation (notice that the longer the period of LIF 
treatment, the slighter became the bands of non-phosphorylated JAK1). Taken these results, 
JAK1 has been hypothesized to play a role in the LIF signaling in JAR cells. 
 
 
JARJEG-3
Control 2 min 5 min 10 min Control 2 min 5 min 10 min
Ph-JAK1
ß-Actin
JAK1
 
 
Fig. 19 Constitutive expression of JAK1 and its phosphorylation after LIF stimulation in 
JEG-3 and JAR cells (n=2) 
Ph-JAK1: phosphorylated JAK1; JAK1: constitutively expressed JAK1. 
Cell groups: Control (non-treated cells); 2 min, 5 min and 10 min (LIF-treated cells. 
Treatment length ranged from 2 min to 10 min). 
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Janus Kinase 2 
 
The Western blot bands below (Fig. 20) derive from experiments in which JEG-3 and JAR 
cells were incubated with LIF during different periods (ranging from 2 to 10 min). 
Phosphorylated JAK2 (Ph-JAK2) and constitutive JAK2 expression (JAK2) were assessed. 
Lymphocytes stimulated with PHA (Lymph + PHA) were used as positive control for JAK2 
expression. .ß-Actin was used as reference control. In JEG-3 cells, very slight signals were 
obtained using the JAK2 antibody, suggesting that this non-phosphoylated form is poorly 
expressed in these cells. Moreover, not very intense bands for phosphorylated JAK2 can be 
identified (with and without LIF stimulation). These bands do not vary significantly after LIF 
stimulation, suggesting that JAK2 is constitutively phosphorylated in these cells, although its 
concentration is not further affected by LIF. In JAR cells, no significant differences were 
observed in the bands of JAK2 after treating cells with LIF (bands from treated cells 
preserved basically the same intensity of control group). Moreover, LIF stimulation seems not 
to be involved in the phosphorylation of JAK2 in JAR cells, since practically no signal for Ph-
JAK2 has been identified. These data support the hypotheses that JAK2 is not phosphorylated 
when JAR cells are stimulated with LIF (or maximally to a marginal degree), and might thus 
not be involved in the process of STAT3 phosphorylation triggered by LIF in these cells. 
 
JARJEG-3
Control 2 min 5 min 10 min Control 2 min 5 min 10 min
JAK2 
ß-Actin
Lymph + PHA
Ph-JAK2
 
 
Fig. 20 Constitutive JAK2 expression and its phosphorylation after LIF stimulation in 
JEG-3 and JAR cells (n=2) 
Cell groups: Lymph + PHA (lymphocytes stimulated with PHA); Control (non-treated cells); 
2 min, 5 min and 10 min (LIF-treated cells. Treatment length ranged from 2 min to 10 min). 
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Janus Kinase 3 
 
The Western blot bands below (Fig. 21) derive from experiments in which JEG-3 and JAR 
cells were incubated with LIF during different periods (ranging from 2 to 10 min). 
Phosphorylated JAK3 (Ph-JAK3) and constitutive JAK3 expression (JAK3) were assessed. 
Lymphocytes stimulated with PHA (Lymph + PHA) were used as positive control for JAK3 
expression. .ß-Actin was used as reference control. The bands below evidence that neither 
non-phosphorylated nor phosphorylated JAK3 are expressed in JEG-3 and JAR cells (with or 
without LIF stimulation). 
 
JARJEG-3
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Fig. 21 Constitutive JAK3 expression and its phosphorylation after LIF stimulation in 
JEG-3 and JAR cells (n=2) 
Ph-JAK3: phosphorylated JAK3; JAK3: constitutively expressed JAK3. 
Cell groups: Lymph + PHA (lymphocytes stimulated with PHA); Control (non-treated cells); 
2 min, 5 min and 10 min (LIF-treated cells. Treatment length ranged from 2 min to 10 min). 
 
 
4.5 – JAK1 Knock-Down in JAR Cells 
 
The previous results obtained by Western blot suggest that LIF is associated with the 
phosphorylation of Janus Kinase 1 (JAK1) in JAR cells. In order to test the hypotheses that a 
reduced expression of this isoform might impair the LIF-induced phosphorylation of STAT3, 
the technique of RNA interference was used to promote JAK1 knock-down in these cells. 
To achieve an efficient gene silencing it is firstly necessary to establish an appropriate siRNA 
transfection method. Among the several possibilities, Nanofectin and Oligofectamine were 
Results
 
51 
used in this work. Different concentrations of these transfection reagents and of the JAK1-
specific siRNA sequence were tested, aiming to obtain the lowest gene expression.  
 
Nanofectin 
 
The Western blot bands below (Fig. 22.1) demonstrate that no effective JAK1 knock-down 
was reached in the experiments using Nanofectin for transfection. Different concentrations of 
the siRNA sequence (6 and 9 µl) and of Nanofectin (10 and 15 µl) were tested. The respective 
concentrations tested in each experiment are seen below in parentheses (after “siRNA” for the 
siRNA sequence and after “N” for Nanofectin). β-actin was used as control. Scrambled 
siRNA (seen as “Scr”), a siRNA with a scrambled non-genomic sequence, was used as 
control to verify possible unspecific effects elicited by transfection. Results are seen next. The 
intensity of the bands was quantified and values are seen in Fig. 22.2. The final value of each 
group comes from the ratio between JAK1 band and its respective β-actin counterpart. Values 
represent the arithmetic mean from both experiments, standardized with the values obtained 
in the non-genomic siRNA group (Scr / scrambled sequence), which was set as 100%. The 
values in Fig. 22.2 evidence that transfection with Nanofectin did not correlate with an 
efficient JAK1 knock-down in JAR cells, even testing different concentrations of this 
transfection reagent and of the siRNA sequence. 
 
 
 
Control Scr siRNA(6)
N(10)
siRNA(6) 
N(15)
siRNA(9) 
N(10)
siRNA(9) 
N(15)
ß-Actin
JAK1 
 
Fig. 22.1   JAK1 knock-down attempt using Nanofectin as transfection reagent (n=2) 
JAK1: constitutively expressed JAK1. 
Cell groups: Control (non-treated JAR cells); Scr (JAR cells treated with a scrambled non-
genomic siRNA sequence); siRNA(x) N(y) (JAR cells incubated with different concentrations 
of JAK1-specific siRNA and Nanofectin. Respective concentration in parentheses). 
JAK1 Knock-Down Attempt Using Nanofectin 
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Fig. 22.2   JAK1 knock-down attempt using Nanofectin for transfection (quantification 
of Western blot bands)  
Cell groups: Control (non-treated JAR cells); Scr (JAR cells treated with a scrambled non-
genomic siRNA sequence); siRNA(x) N(y) (JAR cells incubated with different concentrations 
of JAK1-specific siRNA and Nanofectin. Respective concentrations in parentheses). 
 
 
 
Oligofectamine 
 
In the set of experiments using Oligofectamine, cells were incubated with this reagent and 
with the siRNA sequence for two different periods – 24 and 48 hours. Tested concentrations 
can be seen in Material and Methods. The main goal of the experiments was to obtain a 
reduced JAK1 expression. It was tested if a longer incubation time with the transfection 
reagent and the specific siRNA sequence might be related to a more effective gene knock-
down. The experiment was repeated twice. The Western blot bands depicted in Fig. 23.1 show 
reduced JAK1 signals for the cells incubated with the siRNA sequence, both after 24 and 48 
hours, indicating that relative gene suppression had been achieved. β-actin was used as 
control. Scrambled siRNA (seen as “Scr”), a siRNA with a non-genomic sequence, was used 
as control to verify possible unspecific effects related to transfection.   
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Fig. 23.1   JAK1 knock-down attempt using Oligofectamine for transfection (n=2) 
JAK1: constitutively expressed JAK1. 
Cells groups: Control (non-treated JAR cells); Scr (JAR cells treated with a scrambled non-
genomic siRNA sequence); siRNA (JAR cells treated with a specific siRNA targeting JAK1).  
Oligofectamine was used as transfection reagent in Scr and siRNA groups. Cells were 
incubated with Oligofectamine and the specific siRNA during 24 or 48 hours. 
 
 
In order to quantify these results, band intensity was measured and results are seen in Fig. 
23.2. The values come from the quantification of Western blot bands. The experiment as a 
whole was performed twice. The values obtained by quantification of the bands of JAK1 
(constitutively expressed JAK1) were divided by their respective β-actin counterpart. The 
values presented as next represent the arithmetic mean from both experiments, standardized 
with values obtained in scrambled non-genomic siRNA group (seen as “Scr”), which was set 
as 100%. The values indicate that relative gene suppression was achieved in the groups using 
the JAK1 siRNA sequence (seen in the figure as “siRNA” group). In the experiments testing 
24 h incubation, JAK1 expression fell to approximately 65% (mean value, setting Scrambled 
as 100%). In the experiments testing 48 h incubation, this value was even lower (35%), 
suggesting that a longer incubation period with the specific siRNA sequence correlated with a 
more intense silencing. Considering these results, in all further experiments in which JAK1 
siRNA was used, cells were incubated with this specific sequence for 48 h (assuming that 
gene suppression after this time was more effective than after 24 h). 
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Fig. 23.2   JAK1 knock-down attempt using Oligofectamine for transfection 
(quantification of Western blot bands) 
Cell groups: Control (non-treated cells); Scr (cells treated with a scrambled non-genomic 
siRNA sequence); siRNA (cells treated with a specific siRNA targeting JAK1).  
Oligofectamine was used as transfection reagent in Scr and siRNA groups. Cells were 
incubated with Oligofectamine and the specific siRNA during 24 or 48 hours. 
 
 
 
4.6 – JAK1 Knock-Down and the LIF-Induced Phosphorylation of STAT3 in JAR cells 
 
In a further series of experiments, JAR cells were submitted to JAK1 knock-down (JAK1 
KD) during 48 hours, using Oligofectamine for transfection. Cells were then incubated with 
LIF for different periods (2, 5 and 10 min). Activated tyrosine 705 STAT3 (Ph-STAT3) was 
assessed and β-actin was used as control. Scrambled siRNA (seen as “Scr”), a siRNA with a 
non-genomic sequence, was used as control to verify possible unspecific effects elicited by 
transfection. The Western blot bands depicted in Fig. 24 demonstrate that phosphorylated 
STAT3 is practically absent in the groups that had not been treated with LIF (see Control, 
Scrambled and JAK1 KD groups). Furthermore, LIF treatment was associated with STAT3 
phosphorylation in JAK1-silenced cells. The longer the period of LIF incubation, the stronger 
became the signal of activated STAT3 (see JAK1 KD + LIF groups). These data reveal that 
JAK1 knock-down, at least in the silencing rates obtained in these experiments, was not 
enough to avoid STAT3 Tyr705 phosphorylation in these cells. 
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2 minControl Scr JAK1 
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Ph-STAT3
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Fig. 24 Effect of JAK1 knock-down on the LIF-dependent STAT3 Phosphorylation in 
JAR cells (n=2) 
Ph-STAT3: phosphorylated STAT3 
Cell groups: Control (non-treated cells); Scr (cells treated with a scrambled non-genomic 
siRNA sequence); JAK1 KD (cells treated with the specific siRNA targeting JAK1); JAK1 
KD + LIF (cells treated with the specific siRNA targeting JAK1, subsequently incubated with 
LIF during 2, 5 or 10 minutes). 
Oligofectamine was used as transfection reagent in Scr and JAK1 KD groups. 
 
 
 
4.7 – Proliferation, Migration and Invasion Assays 
 
Functional experiments were performed to analyze possible effects of Leukemia Inhibitory 
Factor (LIF) on the proliferative, migratory and invasive behavior of JAR cells. Moreover, 
knock-down of JAK1 was performed to investigate the role of this JAK isoform on cell 
behavior. Considering that unspecific effects and changes on the functional parameters might 
be triggered by the transfection method itself and/or by the JAK1-specific siRNA sequence, 
cells transfected with a non-genomic sequence (“Scrambled siRNA”) were taken as control in 
the experiments testing JAK1 knock-down. Finally, these cells (with reduced JAK1 
expression) were stimulated with LIF to observe if this cytokine might modify cell behavior, 
even when a component of its signaling cascade had been disrupted. All experiments started 
with about 30,000 cells (aliquots were counted with a Neubauer chamber and cell number was 
extrapolated to total volume of culture). Cells were seeded into individual wells of a 24-well 
plate and were incubated during 24 hours. In those experiments in which LIF was used, cells 
were stimulated throughout the cultivation period at a final concentration of 10 ng/ml. Final 
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cell counting was performed by the flow cytometer. Results are shown as the final cell 
number (arithmetic mean, n=4 for each experiment). 
Fig. 25 evidences the effects of LIF treatment on proliferation, migration and invasion of JAR 
cells. Cells were incubated with 10 ng/ml LIF during 24 hours and their behavior was 
compared to untreated cells (control groups). Data represent the arithmetic mean (values 
obtained using flow cytometry). Error bars show the standard error. Among the functional 
parameters assessed, LIF treatment was associated with a significant increase in cell 
proliferation rate (p<0.05, marked with a *). Differences on cell migration and invasion after 
treating cells with LIF were not significant. 
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Fig. 25 Influence of LIF on the proliferative, migratory and invasive behavior of JAR 
cells (n=4) 
Cell groups: Control (non-treated cells), LIF (cells incubated with LIF during 24 hours). 
 
 
Effects of LIF on Different Functional Parameters 
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The figure below (Fig. 26) shows the effects of JAK1 knock-down (JAK1 KD) on the 
proliferation, migration and invasion of JAR cells. JAK1 KD groups were incubated with the 
specific JAK1 siRNA sequence for 48 hours. Oligofectamine was used for transfection. In the 
scrambled siRNA group (seen as “Scr”), cells were incubated for 48 hours with a non-
genomic sequence using Oligofectamine for transfection. The scrambled group was used to 
verify possible unspecific effects triggered by RNAi. After a 48 hour transfection period, cells 
were submitted to functional tests, which lasted 24 hours. Data represent the arithmetic mean 
from experiments (values obtained using flow cytometry). Error bars show the standard error. 
The results show that JAK1 knock-down correlated with a significant decrease in cell 
migration rate (p<0.05, marked with a *, compared to Control and Scrambled groups). 
Differences on cell proliferation and invasion were not significant. 
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Fig. 26 Effect of JAK1 knock-down on the proliferative, migratory and invasive 
behavior of JAR cells (n=4) 
Cell groups: Control (non-treated cells); Scr (cells treated with a scrambled non-genomic 
siRNA sequence); JAK1 KD (cells treated with the specific siRNA targeting JAK1).  
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The next figure (Fig. 27) demonstrates the effects of LIF on different functional parameters of 
JAK1-silenced cells (JAK1 KD). JAR cells were initially submitted to siRNA transfection 
using Oligofectamine. Cells were incubated with the specific JAK1 siRNA sequence for 48 
hours. After this period, the subgroup JAK1 KD + LIF was treated with LIF for 24 hours. The 
subgroup JAK1 KD was also kept incubated for 24 hours, but without LIF stimulation. Data 
represent the arithmetic mean from experiments (values obtained using flow cytometry). Error 
bars show the standard error. The results below show that LIF treatment was associated with a 
significant increase in the migration rate of JAK1-silenced cells (p<0.05, marked with a *, 
compared to untreated silenced cells). No significant differences on cell proliferation and 
invasion were verified. 
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Fig. 27 Effect of LIF on the proliferative, migratory and invasive behavior of JAK1-
silenced JAR cells (n=4) 
Cell groups: JAK1 KD (cells treated with the specific siRNA targeting JAK1); JAK1 KD + 
LIF (cells treated with the specific siRNA targeting JAK1, subsequently incubated with LIF 
during 24 hours). 
 
Effects of LIF on the Behavior of JAK1-Silenced JAR Cells 
Discussion 
 
59 
5. Discussion 
 
 
5.1 – Influence of LIF and IL-6 on the STAT3 Tyrosine Phosphorylation in Different 
Choriocarcinoma Cell Lines 
 
Cell Culture and Stimulation 
 
In order to test the hypotheses that Leukemia Inhibitory Factor (LIF) and Interleukin-6 (IL-6) 
induce both the tyrosine (tyr705) phosphorylation of STAT3, different choriocarcinoma and 
hybrid cell lines were cultured separately and incubated with these factors at a final 
concentration of 10 ng/ml and 20 ng/ml respectively. Different periods of LIF and IL-6 
stimulation were tested. 
The way cells were incubated and stimulated must be critically analyzed. Fitzgerald et al. 
suggest that cells respond differently to the same factor according to cell physiology, utilized 
concentrations and stimulation periods (Fitzgerald et al. 2010). There is no consensus in 
literature regarding the optimal concentration of LIF and IL-6 for stimulation of trophoblast 
cells and choriocarcinoma cell lines in vitro. Primary trophoblast cells, for example, have 
been stimulated with LIF in concentrations ranging from 10 to 50 ng/ml in experiments 
investigating the effects of this cytokine on trophoblast differentiation (Nachtigall et al. 1996, 
Tapia et al. 2008). The lack of standardized values in in vitro experiments correlates with the 
difficulty in determining the physiological expression of these cytokines during the 
implantation phase. In parts, there are not standardized values because the real concentrations 
of these cytokines have not been completely established during pregnancy. For ethical 
reasons, it is not possible to assess directly the production of LIF by endometrial and 
trophoblast cells during human pregnancy. Furthermore, to date there is neither a validated 
tool to measure LIF expression in endometrial fluids, nor a consensus regarding threshold 
levels associated with implantation success (Brinsden et al. 2009). Beyond that, it should be 
highlighted that the effects of cytokines depend on optimal concentrations, and that 
disturbances in their fine regulation correlate with different pathologies. In these terms, both 
too high and too low levels of LIF expression have been identified in uterine flushings, 
endometrial cell cultures and decidual cells from women suffering from unexplained 
infertility or repeated abortions, suggesting that successful implantation depends on strictly 
regulated LIF levels (Ledee-Bataille et al. 2002, Delage et al. 1995, Piccinni et al. 1998). 
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Considering that a negative feed-back mechanism regulates the LIF signaling pathway, as 
previously described, it is expected that concentrations differing from the optimal one 
promote similar functional effects (Markert et al. 2011). Taking these data together, it is 
appropriate to emphasize the importance of establishing adequate threshold levels in 
experiments testing cytokines such as LIF and IL-6, whose effects strongly depend on their 
concentrations. 
Considering the lack of data in literature concerning these optimal concentrations, we relied 
on the experience of our laboratory to counterbalance this technical limitation. A previous 
study conducted in our laboratory revealed, using immunoblot, that LIF stimulation evokes a 
dose and time-dependent phosphorylation of STAT3 in choriocarcinoma cells. In this study, 
strong signals of STAT3 activity have been detected after LIF stimulation (concentrations 
ranging from 10 to 100 ng/ml LIF) in all periods assessed (LIF treatment during 15, 30 and 60 
min). In the same study, IL-6 elicited a very small degree of STAT3 tyrosine phosphorylation, 
detectable with 20 and 200 ng/ml IL-6, predominantly after a stimulation period of 30 min 
(Fitzgerald et al. 2005b). These results were used as reference in the present work, in which 
cells have been incubated with 10 ng/ml LIF or 20 ng/ml IL-6. Different effects should be 
expected in the groups of cells investigated in this work, since cell physiology depends on the 
specificities of cell metabolism and environment. 
 
Influence of IL-6 and LIF on the STAT3 Tyrosine Phosphorylation 
 
Several growth factors and cytokines are known to activate STAT3, including members of the 
IL-6 family (such as IL-6, IL-11 and LIF), IL-2 family (such as IL-2 and IL-15), epidermal 
growth factor (EGF) and hepatocyte growth factor (HGF) (Corvinus et al. 2003, Heinrich et 
al. 1998).  
As demonstrated by Western blot, the results of this work show, indeed, that LIF is strongly 
associated with the tyrosine phosphorylation of STAT3 in different cell lines, including JEG-
3, JAR, AC1-M59 and ACH-3P cells. The activation of STAT3 was observed even after a 
very short period of LIF stimulation (2 min) in JEG-3 and JAR cells. Similarly to previous 
studies, IL-6 elicited just a marginal degree of STAT3 activation in JEG-3, AC1-M59 and 
ACH-3P cells. Moreover, the results demonstrate that these choriocarcinoma and hybrid cell 
lines respond similarly as trophoblast cells, at least regarding the degree of STAT3 activation 
(Poehlmann et al. 2005). 
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In the context of tumor progression, STAT3 has been described as an inducer of malignant 
cell transformation, leading to cell longevity, hyperplasia and invasiveness (Epling-Burnette 
et al. 2001, Bromberg et al. 1999). Furthermore, it has been implicated in modulation of 
metastatic progression, as the STAT3-dependent transcription cascade has been demonstrated 
to induce angiogenic and inflammatory responses that facilitate tumor metastasis (Ranger et 
al. 2009).  
As previously commented, LIF is assumed to facilitate embryo implantation and is expressed 
by human placenta and endometrium, particularly in the maternal-fetal interface at the time of 
implantation (Paiva et al. 2009, Vogiagis et al. 1996, Aghajanova et al. 2003, Bhatt et al. 
1991). Different cell types, including ovarian stromal cells, hepatocytes and kidney epithelial 
cells are able to express LIF physiologically (Lass et al. 2001, Auernhammer and Melmed 
2000). The expression of LIF by tumor cells themselves has been investigated over the last 
two decades, but studies are still rare and preliminary. Among these studies, LIF expression 
has been identified, using ELISA and/or immunohistochemistry, in human kidney, prostate 
and breast cancer cell lines (Dhingra et al. 1998, Kellokumpu-Lehtinen et al. 1996). In one of 
these studies, endogenously produced LIF correlated with elevated proliferation rates of 
kidney and prostate cancer cells (Kellokumpu-Lehtinen et al. 1996). Another study identified 
high levels of LIF expression in mouse mammary tumors growing in vivo and in their primary 
cultures, as analyzed by RT-PCR and immunohistochemistry, suggesting an 
autocrine/paracrine stimulation of STAT3 activation (Quaglino et al. 2007). To date, there are 
no definitive studies confirming LIF protein expression by trophoblastic tumors and their 
deriving hybrid cell lines. Considering the strong STAT3 phosphorylation elicited by LIF, it 
would be interesting to evaluate if such an autocrine stimulation mechanism exists in the cells 
tested in this work. This would contribute to better understanding the progression of 
trophoblastic tumors. Nonetheless, the indubitable STAT3 tyrosine phosphorylation elicited 
by LIF in trophoblastic and hybrid cell lines observed in this work reveals that these cells are 
at least strongly influenced by LIF, which, in turn, is believed to stimulate cell proliferation 
and induce tumor progression. 
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5.2 – Expression and LIF-Induced Phosphorylation of Janus Kinases in JEG-3 and JAR 
Cells  
 
Once observed that LIF stimulation correlated with the tyrosine phosphorylation of STAT3 in 
JEG-3 and JAR cells, it was investigated which Janus Kinases (JAKs) might have been 
activated after LIF stimulation. In these terms, it was valid to scrutinize which JAK isoforms 
were constitutively expressed in these cells, and which of them might have been 
phosphorylated upon LIF binding to its receptor on cell surface.  
As demonstrated by Western blot in this work, JAK1 and JAK2 are constitutively expressed 
in the choriocarcinoma cell lines JEG-3 and JAR. Practically no JAK3 signal has been 
identified in these cells. These results were reinforced by immunocytochemical studies, which 
evidenced similar patterns of expression, with a few differences. Furthermore, LIF stimulation 
correlated with the phosphorylation of JAK1, but not of JAK3 or JAK2 (in this case, if 
present, just to a very marginal degree). However, the limitations of the use of Western blot 
should be considered for these results, since the presence of small amounts of non-activated 
or activated forms might not have been detected. 
The JAK/STAT pathway is usually referred to as the main signaling mechanism for a vast 
array of hormones, growth factors and cytokines (Rawlings et al. 2004). In mammals, four 
members of the JAK family have been identified, namely JAK1, JAK2, JAK3 and Tyrosine 
Kinase 2 (TYK2) (Yamaoka et al. 2004). Considering their intimate association with cytokine 
receptors, these isoforms are particularly observed in endosomes and cell membrane, where 
they get activated upon cytokine binding, as previously commented (Hofmann et al. 2004, 
Ragimbeau et al. 2003). Jak1, Jak2 and Tyk2 are ubiquitously expressed in mammals, while 
Jak3 is mostly expressed in hematopoietic cells (Kawamura et al. 1994, Musso et al. 1995, 
Tortolani et al. 1995). This data is congruous with the results of this work, in which Western 
blot bands for JAK1 and JAK2, but not for JAK3, have been identified in JEG-3 and JAR 
cells. Due to financial limitations, the expression of Tyk2 has not been evaluated in the 
present work. Additionally, seven STAT isoforms have been observed in mammalian cells 
(STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6). All of them are 
ubiquitously expressed, except STAT4, which is restricted to thymus, myeloid cells and testis 
(Zhong et al. 1994, Costa-Pereira et al. 2011). 
As previously described, several cytokines signal via JAKs, leading to phosphorylation of 
inner ligands, such as the STATs. These are known to translocate to the cell nucleus, where 
they induce the transcription of target genes (Yamaoka et al. 2004). The next table (Table 1) 
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shows some of the main cytokines which signal through specific members of the JAK family 
(Yamaoka et al. 2004). 
 
Table 1   Cytokines signaling through the JAK family 
JAK1 JAK2 JAK3 TYK2 
Common  γ chain 
family: (IL)-2, IL-4, 
IL-7, IL-9, IL-15, IL-
21 
Cytokines sharing 
gp130: IL-6, IL-11, 
oncostatin M, LIF, 
CNF, GM-CSF and 
IFNs 
Hormone-like 
cytokines: GH, PRL, 
EPO, TPO 
Cytokines sharing 
IL-3 receptor: IL-3, 
IL-5 and GM-CSF 
Cytokines sharing 
gp130 
Some IFNs 
Common  γ chain 
family: (IL)-2, IL-4, 
IL-7, IL-9, IL-15, IL-
21 
 
IL-12 
IL (Interleukin), LIF (Leukemia Inhibitory Factor), CNF (Ciliary Neurotrophic Factor), GM-
CSF (Granulocyte-Macrophage Colony-Stimulating Factor), IFN (Interferon), GH (Growth 
Hormone), PRL (Prolactin), EPO (Erythropoietin), TPO (Thrombopoietin). 
 
Finally, the constitutive expression of these JAK isoforms has been assessed in villous and 
extravillous trophoblast cells collected from placental tissues of a healthy woman undergoing 
elective abortion in the 11th week of pregnancy. As it is known, villous trophoblasts are 
involved in gas and nutrient exchange between fetus and mother. They also have endocrine 
and endothelial functions. Extravillous trophoblasts are implicated in the anchoring of 
chorionic villi in the uterus, as long as they are able to migrate through the decidua and invade 
the spiral arteries, finally replacing and remodeling their walls (Tarrade et al. 2001). As 
demonstrated in the Results section, our immunocytochemical analysis identified strong 
signals of JAK1 and JAK2 in villous trophoblast cells, including the inner mononuclear layer 
(cytotrophoblast) and the outer multinucleated syncytiotrophoblast. Mostly observed in the 
cell cytoplasm, both JAKs were believed to be located in endosomes. Additionally, just a 
marginal degree of JAK expression has been identified in extravillous trophoblast cells. 
Practically no signal for JAK3 has been verified in both cell subtypes. The constitutive 
expression of JAKs by cells located in the fetal-maternal interface suggests that the 
JAK/STAT pathway is probably involved in the signaling of different factors present in this 
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microenvironment, some of them potentially involved in the fine regulation of placental 
development, ultimately assuring an adequate environment for embryo growth. 
 
 
5.3 – Trying to Silence JAK1 in JAR Cells 
 
Transfection and RNA Interference 
After observing that JAK1 was constitutively expressed and activated by LIF in JAR cells, it 
was hypothesized that the suppression of JAK1 might disturb the LIF/JAK1/STAT3 
phosphorylation cascade. In humans, it is known that mutations leading to constitutive 
activation or fail in regulation of JAK signaling lead to an array of pathological conditions, 
such as inflammatory diseases,  erythrocytosis and leukemias (Rawlings et al. 2004). In this 
sense, it was investigated if the knock-down of JAK1 might impair STAT3 activation and 
modify cell behavior, altering functional parameters such as cell proliferation, migration and 
invasion.  
In order to promote JAK1 knock-down and test these hypotheses, a set of experiments using 
RNA interference (RNAi) has been performed. As previously described, RNAi is a method to 
knock down gene expression post-transcriptionally, in which a specific mRNA is degraded 
after pairing with the complex RISC-siRNA. In this work it was used a synthetic siRNA that 
is cleaved intracellularly by the enzyme Dicer, originating a siRNA sequence targeted against 
JAK1. Aiming to establish an appropriate transfection method, two different lipid-mediated 
transfection reagents (Nanofectin and Oligofectamine) were tested. Furthermore, cells were 
submitted to different periods of incubation with the siRNA sequence (24h or 48h), in order to 
verify if treatment length could affect the effectiveness of silencing. 
 
Transfection with Nanofectin and Oligofectamine 
 
As previously shown in Results, no reproducible JAK1 knock-down was obtained in the set of 
experiments using Nanofectin as transfection reagent. Even testing different concentrations of 
Nanofectin and siRNA sequence, an insignificant silencing rate has been achieved. At this 
point, it must remembered that cell physiology, which substantially varies in different cell 
groups, may positively or negatively influence the activity of siRNAs. Moreover, a relatively 
high cellular death was observed in the experiments using Nanofectin. This could be 
explained by the fact that some transfection reagents (specially those with a liposomal 
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structure) induce the cellular release of inflammatory cytokines, such as interferon, which is 
able to block translation and to trigger sequence-nonspecific mRNA degradation, ultimately 
promoting the activation of cell apoptosis (Judge et al. 2005, Shinagawa and Ishii 2003). 
Furthermore, it has been suggested that cytoplasmic dsRNA and siRNA duplexes may 
activate the dsRNA-dependent protein kinase R (PKR) in nucleated cells. PKR has been 
related to cell growth inhibition through decreased protein synthesis and stimulation of 
interferon production (Saunders and Barber 2003, Geiss et al. 2001, Levy et al. 1969). In 
these terms, Nanofectin and/or PKR-induced production of interferon might have triggered 
apoptosis in these cells.  
After observing that the experiments with Nanofectin had not been successful, a new set of 
attempts using Oligofectamine were carried out in order to promote JAK1 silencing. As 
demonstrated in Results, these experiments were operated in duplicate using different periods 
of incubation with the siRNA sequence, ultimately revealing better knock-down efficiencies, 
as demonstrated by Western blot. Setting the rate of JAK1 expression of the non-genomic 
sequence (Scrambled-RNA group) as 100%, the experiments using Oligofectamine revealed 
that the constitutive expression of JAK1 had fallen to about 65% after a 24h incubation with 
the siRNA sequence (or 35% knock-down efficiency) and to about 35% after a 48h incubation 
period (or 65% efficiency). Considering these results, the use of Oligofectamine and the 
incubation period of 48h with the siRNA sequence have been considered as standard for all 
subsequent experiments in which JAK1 knock-down was desired (for example, in the 
functional experiments). 
 
Scrambled-siRNA as Control 
 
In the set of experiments in which RNA interference (RNAi) was performed, the outcome of 
JAK1 silencing was assessed by Western blot. In order to quantify and compare knock-down 
efficiency, parallel samples were prepared using untreated cells and scrambled-siRNA (Scr-
siRNA). The latter is composed of a non-genomic siRNA sequence (i.e. it has no match with 
any known human mRNA) which is transfected to verify the specificity of the designed 
siRNA and test the occurrence of unspecific effects possibly triggered by the transfection 
method on the targeted protein. In this work, Scr-siRNA groups were considered as control 
and the results stemming from samples cultured with the Scr-siRNA demonstrated relatively 
few changes on JAK1 expression and on cell behavior profiles when compared with untreated 
cells. However, it should not be discarded that even this non-genomic sequence might trigger 
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unspecific effects on cells, including both up and down-regulation of untargeted genes. In 
these terms, only a global gene expression study might have elucidated the effects of the Scr-
siRNA sequence in these cells. 
  
JAK1 Knock-Down in JAR Cells 
 
With the use of Oligofectamine and a JAK1-specific siRNA sequence, the constitutive 
expression of JAK1 in JAR cells have been reduced to about 35%, as demonstrated by 
Western blot. In order to test the hypothesis that such degree of silencing might have 
influenced the rates of LIF-induced STAT3 phosphorylation, these cells have been treated 
with LIF for different periods of time and the rates of STAT3 phosphorylation have been 
assessed by Western blot. As observed in Results, LIF treatment continued to be associated 
with STAT3 Tyr705 phosphorylation in the JAK1-silenced groups. The longer cells were 
incubated with LIF, the higher were the rates of STAT3 phosphorylation.  
At this point it must be considered that the 65% reduction of JAK1 expression might have not 
been high enough to prevent the activation of STAT3. More experiments are thus necessary to 
reach better knock-down rates. In these terms, it would be interesting to test different siRNA 
sequences targeting JAK1. Generically, the use of a pool of siRNAs with the same target is 
intended to reduce the occurrence of sequence-dependent off-target effects. Additionally, it 
should be considered that not all siRNAs targeting a common sequence demonstrate the same 
knock-down efficiency, so that the use of different siRNAs might equilibrate this disbalance 
(Sledz and Williams 2005). 
It is also plausible that STAT3 might have been activated by mechanisms of crosstalk 
between LIF, JAKs and other pathways. A vast range of pathway intercommunication has 
been described over the last years, such as the cooperation between the JAK/STAT and Notch 
pathways leading to STAT3 phosphorylation (Kamakura et al. 2004). In these terms, LIF 
might have induced STAT3 activation by means other than the regular LIF/JAK/STAT 
pathway.  
Although stimulation with LIF has correlated with practically no phosphorylation of JAK2 in 
JEG-3 and JAR cells in this work (or maximally to a very marginal degree), it should be 
remembered that IL-6 type cytokines have been reported to activate JAK1, JAK2 and TYK2, 
leading to STAT3 phosphorylation (Heinrich et al. 1998). Considering that TYK2 expression 
and activation has not been assessed in this work, it is quite possible that part of the activated 
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STAT3 identified by Western blot had been expressed through the LIF-induced JAK2 and 
TYK2 phosphorylation.  
 
siRNA Limitations and Possible Alternatives 
 
An efficient gene knock-down by means of RNA interference (RNAi) depends on several 
factors. Over the last years different techniques have been developed in an attempt to upgrade 
gene silencing efficiency and to bypass common limitations, ranging from optimization of the 
siRNA design and of transfection methods to avoidance of off-target effects (Harborth et al. 
2003). Designing adequate silencing triggers (considering both siRNA sequence and 
structure), as well as assuring efficient siRNA uptake into the cell by the choice of an 
appropriate transfection method are usually considered crucial steps for an efficient gene 
knock-down (Siolas et al. 2005).  
Cells respond differently to RNAi, and some of them are considered hard-to-transfect, like 
adipocytes and some fibroblast, epithelial and neuronal cell lines (Lab Times datasheet 2010). 
Furthermore, siRNA uptake varies considerably among cells (Kim et al. 2005), as well as the 
concentration of available RISC (Harborth et al. 2003, Gonczy et al. 2000). Further factors 
influencing silencing efficiency include cellular proliferation rate and half-life of target 
message and/or protein (Sledz and Williams 2005). 
Although siRNAs are relatively stable when conditioned in cell culture (Reinhart et al. 2000), 
target silencing activity is usually transient in mammalian systems and persists for 
approximately 3-7 days (Elbashir et al. 2002, Holen et al. 2002, Yang et al. 2001). This is 
valid especially for proliferating cells, and a conceivable reduction of the number of RISCs 
carrying siRNA upon cell division (basically a “siRNA dilution”) has been suggested to 
explain this transient effect (Omi et al. 2004). 
Considering the difficulty in achieving a stable gene silencing in many cells, some 
alternatives for siRNA have been developed. One of them is based on the use of short-hairpin 
RNA (shRNA), whose name derives from the tight hairpin turn present in its structure. 
shRNA technology uses plasmid or viral vectors coding specific sequences that get stably 
integrated into the genome (Czauderna et al. 2003). The transcription of these sequences by 
polymerase III originates shRNAs, which are then processed into siRNAs in the cytoplasm. 
Some vectors have been designed to induce themselves the expression of polymerase III, 
ensuring the shRNA to be constantly expressed and even to be passed through the germline 
(Matsukura et al. 2003, Sijen et al. 2001). The originated siRNAs are subsequently bound to 
Discussion
 
68 
RISC, the complex that will bind and cleave targeted mRNAs, ultimately promoting post-
transcriptional gene silencing (McIntyre and Fanning 2006). The stable integration of the 
vectors into the genome is responsible for a long-term silencing of targeted transcripts in vitro 
and in vivo (Dorsett and Tuschl 2004), turning shRNA a promising tool for RNA interference. 
 
 
5.4 – Cell Behavior After LIF Stimulation and JAK1 Knock-Down 
 
Proliferation 
 
As previously discussed, LIF treatment correlated with an intense tyrosine phosphorylation of 
STAT3 in JEG-3, JAR, AC1-M59 and ACH-3P cells, as demonstrated by Western blot. 
Additionally, JAR cells that had been incubated with LIF exhibited higher proliferation rates 
than untreated cells, as demonstrated by cell counting performed by the flow cytometer. 
Interestingly, these results are similar to a previous study from our laboratory, in which the 
proliferation rates of JEG-3 cells treated with LIF have also been found elevated (Fitzgerald et 
al. 2005b). 
Taken together, this data suggests that the LIF/JAK/STAT3 signaling pathway is implicated 
in regulation of cell proliferation in JAR cells. As it is known, different malignancies have 
been reported to express phosphorylated STAT3 constitutively. This aberrant activity has 
been associated to up-regulation of cell cycle progression and inhibition of apoptosis, leading 
cells to exhibit a malignant behavior (Bromberg et al. 1999, Epling-Burnette et al. 2001). 
Additionally, LIF and STAT3 have been described as promoters of proliferation in certain cell 
types, including neuronal stem cells, human erythroid progenitor cells, trophoblast and JEG-3 
cells (Oshima et al. 2007, Ratajczak et al. 1997, Nakashima et al. 1999, Fitzgerald et al. 
2005b). In rats, the peak of maternal LIF at GD14.5 has been recently demonstrated to be 
followed by an increase of LIF concentration in the fetal serum and fetal cerebral spinal fluid, 
culminating in the proliferation of neuronal progenitor cells in the cerebrum of the fetuses 
(Simamura et al. 2010). Although not confirmed, a temporary elevation of LIF levels in 
human maternal serum has been suggested to play a similar role on human cerebral 
histogeneses (Pitard et al. 1998). In this sense, LIF seems to play a role in the stimulation of 
cell proliferation in the physiological and pathological settings. 
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Migration and Invasion 
 
The process of invasion embraces adhesion, migration and invasion of a cell into a 
determined tissue. Many similarities have been described between trophoblast and tumor cells 
regarding their capability of growing invasively and escaping from damaging responses 
triggered by the immune system (Murray and Lessey 1999). Malignant tumor cells abuse 
these abilities and grow in an uncontrolled fashion, while trophoblast cells, inversely, invade 
in a strictly time and space controlled manner (Bischof and Campana 2000, Murray and 
Lessey 1999). The process of invasion is locally regulated by several factors, including 
hormones, growth factors and cytokines, such as LIF. The interactions between trophoblast 
cells themselves, trophoblast/extra-cellular matrix components and trophoblast/immune cells 
depend on a multitude of extra and intracellular signals (Fitzgerald et al. 2010).  
Maximally observed in the maternal-fetal interface at the time of implantation, LIF has been 
implicated in regulation of cell invasiveness, although reports about its effects on different 
cells types have been controversial (Aghajanova et al. 2003, Vogiagis et al. 1996, Bhatt et al. 
1991). As previously resumed in this work, LIF has been shown to stimulate the production of 
TIMP-1 and -2 by human extravillous trophoblast cells, which act as counterparts of matrix 
metalloproteinases (MMPs) (Tapia et al. 2008). As it is known, MMPs enable trophoblast 
cells to invade maternal decidua upon extra-cellular matrix degradation. Moreover, LIF has 
been shown to induce decreased gelatinase activity in first trimester trophoblast cells 
(Nachtigall et al. 1996, Bischof et al. 1995). Considering that LIF correlates with decreased 
gelatinase activity, increased TIMP production and increased expression of adhesion 
molecules by trophoblasts, it may be concluded that this cytokine exerts an overall inhibitory 
effect on trophoblast invasion (Nachtigall et al. 1996, Bischof et al. 1995).  
In this work, neither the incubation of cells with LIF, nor the disruption of the LIF signaling 
pathway by RNA interference have increased or decreased cell invasiveness significantly. At 
least to JAR cells, LIF stimulation and JAK1 silencing seem not to modify this functional 
parameter. It is possible that LIF exerts an inhibitory effect on the invasive behavior of JAR 
cells, similarly as in trophoblasts. On the other hand, a positive influence of LIF on the 
invasive behavior of JEG-3 cells has been identified using a similar matrigel assay in a 
previous work from our laboratory (Poehlmann et al. 2005). These conflicting results suggest 
that cellular response to LIF may vary among different choriocarcinoma cell lines. Along with 
these results, the effect of LIF on cell invasiveness has been demonstrated to vary even in 
subsets of the same cell sort. For example, the secretion of MMP-9 by laminin receptor α6β4 
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positive cytotrophoblast cells has been demonstrated to be decreased after LIF treatment (thus 
suggesting that LIF inhibits invasion in these cells), whereas an unaltered production of 
MMP-9 has been identified in another cytotrophoblast subset (namely in fibronectin receptor 
α5β1 positive cytotrophoblast cells) (Bischof et al. 1995). In contrast, elevated MMP-9 
production by mouse blastocysts and human trophoblasts has been identified following LIF 
treatment (Harvey et al. 1995, Sunder and Lenton 2000), suggesting that LIF stimulates 
invasion in these cells. On the other hand, another report showed no significant differences in 
MMP secretion by human extravillous trophoblast cells following LIF treatment (Tapia et al. 
2008).  
At this point it must be considered that a balance between MMPs and TIMPs has been 
implicated in modulation of trophoblast invasion, and that normal placentation might be the 
result of this balance (Seval et al. 2004). In these terms, increased levels of gelatinases A and 
B have been identified in human first trimester intermediate trophoblasts (moving the 
aforementioned balance towards invasiveness), whereas increased levels of TIMPS prevailed 
at term (thus attenuating signals that induce invasion) (Polette et al. 1994). Furthermore, the 
specific role of distinct MMPs in the progression of malignancies has not been completely 
clarified, and some reports evidenced unexpected events triggered by them. For example, 
several MMPs (such as MMP-3, -7, -9 and -12) have been demonstrated to generate 
angiostatin from plasminogen, what could in turn limit angiogeneses in peritumoral areas and 
thereby inhibit tumor growth and invasion (Westermarck and Kahari 1999). These results go 
against the simplified hypothesis that the production of MMPs necessarily correlates with 
induction of cell invasiveness. Although not assessed in the present work, the levels of MMPs 
might have been counterbalanced by TIMPs after treating JAR cells with LIF. This could in 
turn justify the apparent irresponsiveness of these cells regarding their invasive behavior.  
Taken together, these data suggest that LIF evokes different responses among cells and that 
its role still needs to be clarified. In this sense, a standard cell response following LIF 
treatment should not be expected. As previously described, JAR cells have been incubated 
during 24 h with this cytokine in this work. Although no significant effect on cell migration 
has been identified after this treatment, JAK1 gene suppression (induced by specific RNA 
interference) correlated with a significant decrease in cell migration rates (p<0.05). This 
suggests, at least to a certain point, that the JAK/STAT signaling pathway might play a role in 
the process of cell migration, independently from LIF. After treating JAK1 silenced cells with 
this cytokine, a significant increase in cell migration was observed in comparison to silenced 
untreated cells (p<0.05), suggesting that silenced cells do respond to LIF. Interestingly, these 
Discussion
 
71 
results were not statistically significant when compared to non-silenced treated cells. If a 24h 
incubation period with LIF did not influence the migratory behavior of non-silenced cells, it 
could be equally expected no differences regarding this parameter to be identified in JAK1 
silenced cells. But JAK1 silenced cells treated with LIF responded differently from JAK1 
silenced untreated cells, suggesting that knock-down, rather than LIF, might have modified 
the migratory profile of these cells. This might be an off-target effect of the RNA interference 
method utilized in this work.  
Finally, it should be considered that many reports investigating the role of LIF on migration 
and proliferation use different concentrations and stimulation periods, since no standard 
protocols can be extrapolated to distinct cell types. Furthermore, it must be remembered that 
each cell line presents differences in cell physiology, and that an expected response to a 
certain cytokine or growth factor may be influenced by a multitude of other factors. In this 
sense, discrepancies can be expected in studies investigating placentation and tumor 
progression. 
 
 
5.5 – The JAK/STAT Signaling Pathway and Pregnancy 
 
As it is known, adequate fetal anchorage and placentation demand strict control of cell 
proliferation, migration and invasion, which is in part regulated by a multitude of factors  
signaling inter and intracellularly (Tapia et al. 2008, Genbacev et al. 1992). Although many 
advances in the field of reproductive biology have been reached over the last decades, the role 
of many factors governing embryo implantation is still far from being completely understood. 
Even the signaling pathways of some cytokines still have to be clarified, and difficulty raises 
as crosstalks among them have been described (Fitzgerald et al. 2008). Studies in this area are 
special focus of interest, since dysregulation of the underlying mechanisms governing embryo 
implantation has been associated to adverse pregnancy outcome and infertility (Dimitriadis et 
al. 2010). 
In this sense, dysregulation of LIF and its underlying JAK/STAT signaling pathway has been 
repeatedly associated to impairment of human and murine pregnancies (Dimitriadis and 
Menkhorst 2011). In murine models, for instance, disturbances in the LIF/JAK/STAT 
pathway have been related to poor pregnancy outcome. Lif-deficient mice are infertile because 
their blastocysts are unable to implant, although this situation can be reversed by infusion of 
LIF into the uterus (Stewart et al. 1992). Furthermore, Stat3 knock-out embryos degenerate 
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and die shortly after implantation (Takeda et al. 1997), while Socs3 knock-out embryos 
present impaired placental development, with reduced formation of spongiotrophoblast, 
labyrinthine layers and increased trophoblast giant cell differentiation (Fitzgerald et al. 2009). 
Specific deletions in the LIF underlying pathway have been tested in mice over the last 
decades in an attempt to understand the role of its factors, and the outcome of these 
experiments has been summarized in Table 2: 
 
Table 2   Outcome of specific deletions in the LIF/JAK/STAT signaling pathway in mice 
Lif-deficient mice  
(females lacking functional 
LIF gene) 
Failure of blastocyst implantation, although blastocysts are 
viable (Stewart et al. 1992) 
Lifr-deficient mice Impaired placenta function, severe osteopenia, death within 
24 h after birth (Ware et al. 1995) 
gp130-mutant mice  
(with deletion of all STAT-
binding sites)  
Failure of blastocyst implantation, impaired humoral and 
mucosal immune and hepatic acute phase responses (Ernst et 
al. 2001) 
 
Jak1-deficient mice 
40% lower weight, defective lymphoid development and 
function (with severe combined immunodeficiency - SCID), 
perinatal death due to neurological deficits (with deficient 
suckling) (Rodig et al. 1998, Yamaoka et al. 2004) 
Jak2-deficient mice Embryo death due to disrupted erythropoiesis. Normal 
placenta (Neubauer et al. 1998, Parganas et al. 1998)  
 
Jak3-deficient mice 
Severe combined immunodeficiency (SCID), with defects in 
B lymphocyte maturation an T lymphocyte activation (Park et 
al. 1995, Thomis et al. 1995) 
 
Tyk2-deficient mice 
Susceptibility to parasite infection, due to defective response 
to lipopolysaccharide (found in the outer membrane of Gram-
negative bacteria) (Karaghiosoff et al. 2003)  
 
 
Such studies find an obvious resistance in humans due to ethical reasons. The role of many 
factors expressed in pregnancy and their underlying pathways are then hypothesized to be 
similar in humans. Consequently, such extrapolations must be critically analyzed.  
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Anyway, disturbances in the LIF/JAK/STAT pathway have also been related to poor 
pregnancy outcome in humans. For example, decreased production of LIF mRNA by decidual 
leukocytes correlates with unexplained recurrent abortion (Piccinni et al. 2000). Furthermore, 
abnormal persistence of the LIF receptor on extravillous trophoblast cells and decreased 
SOCS3 expression in the villous tissues have been identified in placental beds from women 
suffering of early-onset pre-eclampsia (Fitzgerald et al. 2010, Reister et al. 2006). The 
placenta of women who develop this condition is characterized by poor decidual invasion and 
excessive proliferation of immature trophoblast (Reister et al. 2006, Redline and Patterson 
1995).The importance of this data lye in the fact that pre-eclampsia is considered the major 
cause of maternal morbidity in antenatal care in developed countries, and women who have 
presented this condition are at increased risk of cardiovascular diseases later in life (Redman 
and Sargent 2005, Smith et al. 2001). Moreover, some women with pre-eclampsia also 
develop intrauterine growth restriction, a condition associated with impairment of maternal 
spiral arteries remodeling (Fisher 2004). As it is known, intrauterine growth restriction 
triggers perinatal mortality and the babies who have suffered from it are at an elevated risk of 
developing diabetes and cardiovascular complications in adult life (Solomon and Seely 2004). 
Taken together, this data highlights the importance of LIF and the JAK/STAT signaling 
pathway for a successful early pregnancy. They also justify the efforts in understanding the 
biological mechanisms governing embryo implantation and development, since disturbances 
in these pathways partly account for some of the most important disorders related to 
pregnancy. 
 
 
5.6 – The JAK/STAT Signaling Pathway and Cancer 
 
Over the last years, it has been investigated the components of abnormal microenvironments 
that play a role in the development of tumors, supporting the proliferation and invasive 
behavior of malignant cells (Sanz-Moreno et al. 2011, De Wever and Mareel 2003). These 
microenvironments are constituted of extracellular components, as well as tumor, stromal, 
inflammatory and immune cells (Mantovani et al. 2008). The regulation of these 
microenvironments is in part orchestrated through the expression of a multitude of factors, 
including chemokines, cytokines and their receptors (such as those of the IL-6 family), as well 
as by proteases and growth, survival and angiogenic factors (DeNardo et al. 2008, Mantovani 
et al. 2008, Bromberg and Wang 2009, Coussens and Werb 2002). 
Discussion
 
74 
Several cytokines present in these microenvironments have been reported to signal through 
the JAK/STAT signaling pathway, in which the activation of JAKs leads to the 
phosphorylation of members of the STAT family, among other substrates, resulting in gene 
expression (Pedranzini et al. 2004, Yu et al. 2009). 
Considered as key components for tumor progression, some cytokines are implicated, among 
others, in extracellular matrix remodeling, a process that involves integrins, 
metalloproteinases and force generation (Meshel et al. 2005, Gaggioli et al. 2007, Provenzano 
et al. 2006). The importance of actomyosin contractility, for instance, is evidenced by its role 
in the process of tumor cell movement. Carcinoma-associated fibroblasts use this contractile 
force, along with their proteolytic activity, to create tracks for tumor migration, enabling 
tumor cells to move as individual cells or in a collective fashion (Gaggioli et al. 2007, Sanz-
Moreno et al. 2011). Furthermore, actomyosin contractility is believed to provide malignant 
cells the mechanical strength necessary to resist to the shear forces of the circulatory system 
during the process of metastasis (Sanz-Moreno et al. 2008, Gaggioli et al. 2007, Pinner and 
Sahai 2008). This force generated by actomyosin contraction has been shown to depend on 
cytokines, such as LIF, signaling through the receptor subunit gp130-IL6ST and the kinases 
JAK1 and Rho-Rho (ROCK) (Sanz-Moreno et al. 2011). At the same time, cytokines induce 
recruitment of inflammatory cells, leading to expression of proteases, proinvasive factors and 
more cytokines (Coussens and Werb 2002). 
As previously commented, dysregulation of the JAK/STAT signaling network has been 
implicated in a multitude of pathological conditions. Aberrant JAK activation, for example, 
has been associated with the progression of leukemias and inflammatory disease (Rawlings et 
al. 2004, Yamaoka et al. 2004). Although not completely understood, dysregulated cytokine 
signaling has been suggested to be the most common mechanism leading to aberrant JAK 
activation, and this mechanism has been identified in hematologic malignancies, as well as in 
prostate and breast cancer (Pedranzini et al. 2006). Similarly, aberrant STAT3 activity has 
been implicated in cell cycle progression and apoptosis inhibition, inducing cells to develop a 
malignant behavior (which embraces hyperplasia, longevity and invasiveness) (Epling-
Burnette et al. 2001, Bromberg et al. 1999). STAT3 has also been demonstrated to regulate 
the expression of proteinases involved in tumor invasion, such as matrix metalloproteinases 
MMP-1, MMP-2, MMP-9 (Song et al. 2008, Itoh et al. 2006). Additionally, aberrant 
activation of STAT3 correlates to the overexpression of mucin-1, which has important roles in 
tumorigenesis, mediating cancer cell survival and metastasis (Gao et al. 2009). Indeed, 
STAT3 can be considered a mediator of oncogenesis, and its constitutive activation has been 
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reported in a variety of malignancies, including brain, breast, lung, prostate, melanoma and 
squamous cell carcinomas (Bromberg et al. 1999, Catlett-Falcone et al. 1999, Pedranzini et al. 
2004). As demonstrated in this work, LIF correlated with an intense phosphorylation of 
STAT3 in different choriocarcinoma cell lines. It is so plausible to hypothesize that an 
aberrant JAK/STAT3 activation in these cells might be triggered, at least in parts, by this 
cytokine, leading to cells to develop and perpetuate a malignant behavior. 
 
 
5.7 – Conclusion and Perspectives 
 
Conclusion 
 
This work intended to clarify the function and regulation of some components of the 
JAK/STAT pathway involved in the signaling of LIF in different choriocarcinoma cell lines. 
As previously commented, a set of experiments was performed in order to analyze the 
influence of this cytokine on the STAT3 phosphorylation and its underlying mechanisms, 
such as the activation of some members of the Janus Kinase family. Therefore, it has been 
investigated which members of this family were constitutively expressed and activated upon 
LIF treatment in these cells. The presence of these JAK members in human placental tissues 
was additionally investigated by immunocytochemical tests. By applying functional assays, 
the effects of LIF on cell behavior have been investigated. Furthermore, the technique of 
RNA interference was used trying to establish an efficient JAK knock-down. Finally, the 
effects of this gene silencing on cell behavior and on possible disturbances in the JAK/STAT 
signaling pathway have been scrutinized. 
Taken together, the results of this work demonstrate that: 
? LIF (but not IL-6) induces an intense STAT3 phosphorylation in the tested 
choriocarcinoma cell lines; 
? JAK1 and JAK2 are constitutively expressed in JAR cells, but just to a marginal 
degree in JEG-3 cells; 
? Human villous syncytio and cytotrophoblast cells express JAK1 and JAK2; 
? LIF treatment induces JAK1 phosphorylation in JAR cells and JAK2 activation in 
JEG-3 cells; 
? LIF treatment correlates with a significant increase in the proliferation rate of JAR 
cells, but does not significantly influence their migratory and invasive behavior; 
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? JAK1 knock-down was more efficiently achieved by using Oligofectamine than 
Nanofectin as transfection reagent;  
? LIF treatment induces STAT3 phosphorylation in JAK1-silenced cells, suggesting that 
other components beyond JAK1 may be involved in the signaling of this cytokine in 
JAR cells; 
? JAK1-silenced cells respond differently from non-silenced cells. After LIF treatment, 
JAK-1 silenced cells demonstrated higher migration rates. On the other side, 
proliferation and invasion rates maintained unaltered. 
 
Perspectives 
 
Over the last years, the role of cytokine signaling in regulation of tumor cell dissemination 
has been investigated. A multitude of factors, including high levels of cytokines, are found 
within tumor microenvironments, and  these factors are partially produced and regulated by 
cancer cells themselves or by tumor-associated cells, such as fibroblasts and inflammatory 
cells  (Melnikova and Bar-Eli 2009, Chen et al. 2008). Some of the cytokines mediating 
cancer progression have been shown to signal through common specific pathways, such as the 
JAK/STAT signaling pathway. Key factors of this network have been demonstrated to be 
similarly expressed in a variety of tumors, such as constitutively activated STAT3, which has 
been identified, as previously cited, in brain and lung carcinoma, melanoma, choriocarcinoma 
etc (Fitzgerald et al. 2005b, Bromberg et al. 1999, Pedranzini et al. 2004). 
The JAK/STAT signaling pathway has been recently suggested to provide the basis for 
sustained responses necessary for tumor invasion, at least in human melanoma (Sanz-Moreno 
et al. 2011). In these terms, a positive feedback resulting in enhanced STAT3 phosphorylation 
has been identified, with gp130-IL6ST, JAK1 and ROCK exerting central roles in the 
signaling network modulating the motility of tumor cells. Although the STAT3-dependent 
process of tumor development has not been completely clarified, aberrant STAT3 has been 
implicated in tumor growth and survival, angiogenesis, immunological masking, invasion and 
metastasis (Turkson 2004, Haura et al. 2005, Yue and Turkson 2009). 
Reasonably, the comprehension of the role of the several factors involved in cancer initiation 
and progression can provide the bases for the development of therapeutic agents targeting its 
key components and pathways, including aberrant signaling transduction, what can potentially 
result in inhibition of tumor invasion and metastasis. As a matter of fact, therapeutic agents 
intended to block cancer progression have been developed over the last years. Among them, 
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tetracyclic pyridone 6 (P6) is a pan-JAK inhibitor which has been demonstrated to promote 
growth arrest and apoptosis of primary myeloma cells and myeloma-derived cell lines, both in 
culture and grown on bone marrow-derived stromal cells (Pedranzini et al. 2006). 
Additionally, tyrphostin AG490 is a JAK2 inhibitor which has been shown to restrain the 
growth of tumor cells in vitro and in vivo in acute lymphoblastic leukemia (Meydan et al. 
1996, Levitzki 1996), highlighting the therapeutic potential of JAK blockade in the treatment 
of some tumors. Nevertheless, there is some concern about the amount of inhibitor necessary 
for this effect on tumor growth and the specificity of these factors, particularly of AG490 
(Thompson 2005, O'Shea et al. 2005).  
Aberrant STAT3 expression has also been targeted in molecular therapy, and STAT3 
inhibitors have been developed since 2001 (Turkson et al. 2001). The most explored strategies 
targeting the STAT3 signaling pathway have been recently reviewed (Yue and Turkson 2009) 
and comprise:  
- direct targeting of STAT3: dimerization inhibitors, DNA binding inhibitors and N-terminal 
domain inhibitors; 
- indirect targeting of its intrinsic upstream components. 
Much of the efforts in the field of STAT3 biological inhibition have been directed at 
disruption of dimerization. Although many STAT3 inhibitors have been reported to date, just 
a few have demonstrated good activity in terms of antitumor cell effect, and practically none 
of them is near clinical development (Yue and Turkson 2009). Consequently, it is still too 
soon to predict how patients will benefit from STAT3 inhibitors as anticancer agents, and new 
efforts on the targeting of the many sites of the STAT3 activation process shall probably arise 
in the near future. 
In the field of reproduction, LIF and the JAK/STAT signaling pathway also deserve some 
comments. As previously cited in this work, LIF is regarded as a central factor regulating 
embryo implantation, both in rodents and primates, inasmuch as it stimulates anchorage of the 
trophoblast, in a process comprising cell adhesion and invasion (Dimitriadis et al. 2010, Singh 
et al. 2011). The observation that women suffering from repeated implantation failure and 
unexplained abortion present mutation in the LIF gene (Steck et al. 2004) prompted scientists 
to develop therapies to restore LIF levels during the implantation window. In fact, the 
importance of LIF for implantation in animal models is highlighted by the observation that 
embryos fail to implant in Lif-deficient female mice, and implantation can be restored after 
LIF supplementation (Stewart 1994). Additionally, it was recently demonstrated that women 
have greater chance of getting pregnant when they present strong LIF immunoreactivity 
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during the implantation phase (Serafini et al. 2009). In this context, the use of recombinant 
human LIF (r-hLIF) has been tested in preclinical and clinical trials in women with recurrent 
implantation failure and undergoing in vitro fertilization. It could be expected that r-hLIF 
administered SC might counterbalance the possibly weaker expression of endometrial LIF in 
these women, with consequent improvement in implantation rates. Unfortunately, a recent 
multicenter study testing this hypothesis demonstrated discouraging results, with lower 
clinical pregnancy rates observed in women receiving r-hLIF than in those receiving placebo 
(Brinsden et al. 2009). In the same study, the authors emphasize the difficulty in recruiting 
patients with LIF dysregulation, since there is neither a validated tool to assess LIF 
expression, nor an endometrial LIF threshold level below which there is a correlation with 
recurrent implantation failure. The overcome of such limitations, with the establishment of 
normal and pathological threshold levels of LIF expression, shall facilitate the development of 
new therapies targeting LIF-related implantation disorders. 
On the other hand, maintaining the endometrium in a non-receptive state has also been goal of 
studies, particularly of those concerning the development of novel contraceptive therapies, in 
which critical factors governing endometrial receptivity are intended to be targeted 
(Dimitriadis et al. 2010). In these terms, nonhormonal LIF inhibitors have been tested in mice, 
with consequent prevention of implantation through the targeting of LIF action in endometrial 
luminal epithelial cells (White et al. 2007). Nevertheless, these results still need to be 
validated in primates. 
In conclusion, one can say that LIF and its underlying JAK/STAT signaling pathway have 
been intensively investigated over the last years, but a lot of effort is still necessary to 
completely understand the role of these factors in cell signaling. Many members of this 
pathway have been demonstrated to be diffusely distributed in the organism and are involved 
in the transmission of a vast array of signals governing central functions, both in the 
physiological and pathological settings. The understanding of the role of these factors shall 
ultimately contribute to the development of therapies targeting cancer and pregnancy-related 
disorders. We hope that the experiments and results of this work have contributed to better 
comprehend some aspects of these multifunctional and complex signaling mechanisms. 
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Equipment, Material and Reagent Specifications 
 
Equipments 
 
Autoclave      KSG-112-Olching 
Balance 
Basic      Satorius 
Blot Apparatus     Biometra 
Centrifuges 
Biofuge 13     Heraeus 
Labofuge T     Heraeus 
Mikro 22 R     Hettich 
Universal 30 F    Hettich 
Counting Chamber     Optik Labor 
Electrophoresis Chamber    PEQLAB Biotechnology GmbH 
Film Cassette      Kisker 
Flow Cytometer     BD 
FACSCalibur 
Fluorescence Microscope    Zeiss 
Axioplan 2 
Gel Documentation System    Biostep GmbH 
MF-ChemiBIS 3.2 
Heating Plate MR 3001    Heidolph 
Incubator      Heraeus  
Hera Cell 
Laminar Airflow Cabinet Steril GARD Hood Baker Company 
Microscope      Zeiss 
Axiovert 25 
Orbital Shaker      Heidolph  
Polymax 1040 
Pipettes      Eppendorf 
Spectrophotometer     Bio Varian 
Cary UV 50 
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Thermomixer Comfort    Eppendorf 
Vortex-Genie 2     Scientific Industries 
 
Materials 
 
Cell Culture Flask                                                    
50 ml, 175 cm2    Greiner 
Cell Culture Plates                                                       
6, 24-well plates    Greiner 
Cuvettes      Greiner 
Eppendorf Tubes     Sarstedt 
0.5, 1.5, 2.0 ml 
Falcon Tubes      Greiner 
15 ml, 50 ml 
Film 
Hyperfilm     Amersham Pharmacia Biotech 
MIN- R 2000     Kodak 
Filter 
Ultrafree-15     Millipore 
PVDF Membrane     Amersham Pharmacia Biotech  
Hybond-C Extra                                       
 
Chemicals and Reagents 
 
1,4-Dithiothreitol (DTT)    Roth 
5x siRNA Annealing Buffer    Ambion 
Acetic Acid      Roth 
Ammonium Persulfate (APS)   Roth 
Bis-/Acrylamide (AA/BAA)    Roth 
Bromophenol Blue     Roth 
Chemiluminescent Substrate 
LumiGLO        Cell Signaling Technology 
Carboxyfluorescein Succinimidyl Ester (CFSE)  
Cell Lyses Buffer     Cell Signaling Technology 
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Developer and Fixer Solutions   Kodak 
DMEM      Bio Whittaker 
Electrolytic Buffer     Peqlab 
Ethanol      Roth 
FACS Clean      BD 
FACS Flow      BD 
FACS Lysing      BD 
FACS Rinse      BD 
GBSS       Sigma 
Glycerin      Roth 
Goat Serum      DAKO 
Lymphocyte Separation Medium   PAA 
Matrigel      BD 
Methanol      Roth 
Molecular Weight Marker 
Prestained Protein Marker   BioLabs 
Precision Plus ProteinTM Standards  BIO-RAD 
Nanofectin Diluent     PAA 
Nuclease Free Water      Ambion 
Sodium Chloride (NaCl)    Roth 
Sodium Dodecyl Sulphate (SDS)   Roth 
Sodium Hydroxide (NaOH)    J.T. Baker 
OligofectamineTM  Reagent    Invitrogen 
Optimem      Bio Whittaker 
Paraformaldehyde     Sigma 
PBS       Biochrom AG 
Penicillin/Streptomycin    PAA 
Poly-L-Lysin      Sigma 
Ponceau S      Roth 
Protein-Assay      BIO-RAD 
Proteinase Inhibitor Cocktail    Sigma 
RPMI 1640      PAA 
TEMED      Pharmacia Biotech 
Tris-Base      Sigma 
Appendix 
 
VI 
 
Tris-HCL      Sigma 
Trypan Blue      Sigma 
Trypsin/EDTA     Lonza 
TWEEN 20      Roth 
Zymed Blocking Solution    Invitrogen 
 
Antibodies 
 
Rabbit anti-human ß-Actin   Cell Signaling Technology 
Anti-rabbit IgG    Cell Signaling Technology  
Goat anti-rabbit IgG-Cy3   Dianova 
 
Oligonucleotide Sequences 
 
JAK1 siRNA Sequences (Eurogentec): 
 
Sense:  5’ GCA GGU GGC UGU UAA AUC 3’ U99 
Antisense: 5’ AGA UUU AAC AGC CAC CUG 3’ C99 
 
Non-genomic Oligonucleotide Sequences: 
 
Stat3 102 (Control): 
Sense:  5’ GCC ACU UAU AAA UUC GUU Ctt 3’ 
Antisense:  5’ GAA CGA AUU UAU AAG UGG Ctt 3’ 
 
Buffers, Solutions and Gel Composition 
 
10 x Running Buffer: 
0,24 M  Tris-Base 
1,9 M   Glycine 
0,1%   SDS   pH 8,5 
 
10 x Tris-Glycine-Buffer: 
0,12 M  Tris-Base 
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0,96 M  Glycine     
 
Transference Buffer: 
1 x   Tris-Glycine-Buffer 
20%   Methanol 
 
5 x Loading Buffer: 
50 mM  Tris-HCL 
2%   SDS 
0,002%  Bromphenol Blue 
0,1 M   DTT 
10% (w/v)  Glycerin 
 
4 x Lower Tris: 
1,5 M   Tris-Base 
0,4%   SDS   pH 8,8 
 
4 x Upper Tris: 
0,5 M   Tris-HCL 
0,4%   SDS 
 
Ponceaus-S-Staining Solution: 
0,1%   Ponceau S 
5%   Acetic Acid 
 
Ponceau-S-Decolourising Agent: 
0,8% (w/v)  NaOH 
 
PBS Tween 20 (Wash Buffer) 
2,4g   Tris-Base 
9,0g   NaCl 
0,1%   Tween 20  pH 7,4 
 
PBS 10x (1M) for Immunocytochemistry 
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87,9g   NaCl 
2,74g   KH2PO4 
11,35g   Na2HPO4  pH 7,2 
 
PBS/tween 20 (0,03%) for Immunocytochemistry 
75µl tween20 in 25ml PBS 0,1M 
 
 
 
